

STN SEARCH TRANSCRIPT 10/645312

Connecting via Winsock to STN

"DELOMBAERT CRF ANTAGE"

Welcome to STN International! Enter x:x

LOGINID:SSPTA1623ZCT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOX CENTER reloaded
NEWS 8 MAR 22 REGISTRY: New updated monthly; patent information enhanced
NEWS 9 MAR 22 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 10 MAR 22 PATDPAFULL - New patent database available
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 12 APR 04 GBFULL enhanced with additional patent information and new fields
NEWS 13 APR 04 ENBASE - Database reloaded and enhanced
NEWS 14 APR 18 New CAS Information Use Policies available online
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs), based on application date in CA/Cplus and USPATFULL/USPAT2, may be affected by a change in filing date for U.S. applications.
NEWS 16 APR 26 Improved searching of U.S. Patent Classifications for U.S. patent records in CA/Cplus
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from CHEMCATS
NEWS 19 JUN 06 STN Patent Forum to be held in June 2005
NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS 21 JUN 13 RUSSIAPAT: New full-text patent database on STN
NEWS 22 JUN 13 FBFULL enhanced with patent drawing images
NEWS 23 JUN 20 MEDICONF to be removed from STN
NEWS 24 JUN 27 MARPAT displays enhanced with expanded G-group definitions and text labels

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0j(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTERN General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005

>> FILE REC
COST IN U.S. DOLLARS SINCE FILE
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUN 2005 HIGHEST KN 053177-57-8
DICTIONARY FILE UPDATES: 28 JUN 2005 HIGHEST KN 053177-57-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added. *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registries.html>

>> ...Testing the current file... screen

ENTER SCREEN EXPRESSION OR (END):end

>> Uploading C:\Program Files\Stnexp\Queries\DELOMBAERT CRF ANTAGE.str



chain nodes :
17 19
ring nodes :
1 4 5 6 7 8 9 10 11 12
chain bonds :
3-19 6-7 12-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/nova bonds :
3-19 6-7 7-8 7-12 8-9 9-10 10-11 11-12 12-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:C,N
G2:CH,X,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO
G3:O,N
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 17:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

>> que L1

L2 QUE L1

>> D L1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

>> S L2
SAMPLE SEARCH INITIATED 14:42:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 251 TO ITERATE

100.0% PROCESSED 251 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00:00.01 50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4070 TO 5970
PROJECTED ANSWERS: 608 TO 1472

L3 50 SEA SSS SAM L1

>> S L2 SSS FULL
FULL SEARCH INITIATED 14:44:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5294 TO ITERATE

100.0% PROCESSED 5294 ITERATIONS 978 ANSWERS
SEARCH TIME: 00:00.01

L4 978 SEA SSS FUL L1

>> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE
ENTRY SESSION
FULL ESTIMATED COST 162.19 162.40

FILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is available for records published or updated in Chemical Abstracts after December 26, 1996, unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 28 Jun 2005 (20050628/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

>> S L4 51 L4

>> D 1-51

L5 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:289493 CAPLUS
DN 1421:355283
TI Preparation of triazolopyrazines, pyrazolopyrimidines, pyrazolopyridines, pyrazolopyrazines and related compounds as corticotropin releasing factor (CRF) receptor ligands.
IN Hodgetts, Kevin J.; John, Stanley; Moorcroft, Neil; Shutske, Greg; Kaiser, Bernd; Yamaguchi, Yasuhide; Ge, Ping; Horvath, Raymond F.
PA Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.

SO PCT Int. Appl., 187 pp.
Coden: PIYKD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 20050284890 A2 20050331 WO 2004-US28663 20040903
WO 20050284890 A3 20050502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
US 2005070542 A1 20050331 US 2004-933700 20040903
PRAI US 2003-50033P P 20030903
OS MARPAT 142:355263

LS ANSWER 2 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:238985 CAPLUS
DN 142:316843
TI Preparation of heterocaryl fused pyridines, pyrazines, and pyrimidines as CR1 receptor ligands
IN Ge, Ping; Horvath, Raymond F.; Zhang, Lu Yan; Yamaguchi, Yasuchika; Kaiser, Bernd; Zhang, Yuchun; Zhang, Sueming; Zhao, He; John, Stanley; Moorcroft, Neil; Shutske, Greg
PA Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.
SO PCT Int. Appl., 290 pp.
Coden: PIYKD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2005028906 A2 20050317 WO 2004-US28869 20040903
WO 2005028906 A3 20050502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
US 2005113379 A1 20050526 US 2004-933834 20040903
PRAI US 2003-50044P P 20030905
OS MARPAT 142:316863

LS ANSWER 3 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:179880 CAPLUS
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amine Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines. [Erratum to document cited in CA142:198023]
AU Thompson, Amy E.; Hughes, Gregory; Bateman, Andrei S.; Bryce, Martin R.;

PA Biofocus Discovery Ltd., UK
SO Brit. UK Pat. Appl., 133 pp.
Coden: BAYYDU
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI GB 2400101 A1 20040106 GB 2003-7214 20030328
WO 2004085409 A2 20040107 WO 2004-GB1399 20040326
WO 2004085409 A3 20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2003-7214 A 20030328
OS MARPAT 141:314349
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 7 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:759828 CAPLUS
DN 141:360774
TI Preparation of pyrazinocarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway
IN Munchhoff, Michael J.
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 26 pp.
Coden: USYXCO
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2004180905 A1 20040916 US 2004-798198 20040310
WO 200408982 A1 20040923 WO 2004-IB581 20040223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
PRAI US 2003-4537849 P 20030311
OS MARPAT 141:260774

LS ANSWER 8 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:515493 CAPLUS
DN 141:71565
TI Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II diabetes
IN Chen, Shaoping; Corbett, Wendy Lee; Gwertzman, Kevin Richard; Haynes, Nancy-Ellen; Kester, Robert Francis; Memmolo, Francis A.; Mischke, Steven Gregory; Oian, Yimin; Sarabu, Ramakanth; Scott, Nathan Robert; Thakkar,

Parry, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durham, DH1 3LE, UK
SO Journal of Organic Chemistry (2005), 70(7), 2884
Coden: JOCHEA; ISSN: 0022-3263
PB American Chemical Society
DT Journal, Errata
LA English
LS ANSWER 4 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1067792 CAPLUS
DN 142:198022
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amino Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines
AU Thompson, Amy E.; Hughes, Gregory; Bateman, Andrei S.; Bryce, Martin R.; Parry, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durham, DH1 3LE, UK
SO Journal of Organic Chemistry (2005), 70(1), 388-390
Coden: JOCHEA; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:996174 CAPLUS
DN 141:410966
TI Preparation of pyrazinamine derivative as CRF1 receptor antagonists
IN Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min; Hoffmann, Robert L.; Verhoest, Patrick R.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 57 pp.
Coden: PIYKD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004099201 A1 20041118 WO 2004-IB1553 20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
US 2005038040 A1 20050217 US 2004-840485 20040506
PRAI US 2003-469486P P 20030509
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 6 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:612360 CAPLUS
DN 141:314349
TI Preparation of libraries of compounds (e.g. pyridines, pyrazines, imidazopyrazines) capable of binding to the active site of protein kinases
IN Harris, John; Church, Nicola; Proud, Andrew; Kling, Marcel; Vickery, Benjamin D.

Khalilij Chahibhai
F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 243 pp.
Coden: PIYKD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004052869 A1 20040624 WO 2003-EP14055 20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, VC, VN, YU, ZA, ZM, ZW
BW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
US 2004147748 A1 20040729 US 2003-732838 20031210
PRAI US 2002-422806P P 20021212
US 2002-524531P P 20031124
OS MARPAT 141:17165

LS ANSWER 9 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182851 CAPLUS
DN 140:217663
TI Preparation of 5-substituted-2-arylpypyrazines as modulators of CRF receptors
IN Yoon, Taeyoung; Ge, Ping; Delcombaert, Stephane; Horvath, Raymond
PA Neurogen Corporation, USA
SO PCT Int. Appl., 137 pp.
Coden: PIYKD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004018437 A1 20040304 WO 2003-US26141 20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
BW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, OO, GW, ML, MR, NE, SN, TD, TG
US 24956197 A1 20040311 CA 2003-24956197 20030820
US 2004106620 A1 20040603 US 2003-645312 20030820
PRAI US 2002-405013P P 20020820
US 2003-362141 W 20030820
OS MARPAT 140:217663

APPlicants
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 10 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:60488 CAPLUS
DN 140:128431
TI Preparation of pyrazine and quinoxaline derivatives as chemokine receptor CR4 antagonists and medicinal use thereof
IN Habashita, Hiroshi; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki;

10/645312

Sagawa, Kenji
Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 353 pp.
Coden: PIXKD2
DT Patent
LA Japanese
PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004007472 A1 20040122 WO 2003-JP8654 20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
EN: GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EZ, MD, NU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FE, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
EP 1541563 A1 20050615 EP 2003-764137 20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI JP 2002-206879 A 20020710
WO 2003-JP8654 W 20030708
OS MARPAT 140:120431
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 11 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:20338 CAPLUS
DN 140:70701
TI N-heteroaryl-N'-heterocyclureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew; Dong, Youhao; McCombie, Stuart W.; Wu, Yusheng
PA USA
SO U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 26,651.
Coden: USYXCO
DT Patent
LA English
PAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2004006086 A1 20040108 US 2002-177345 20020620
US 200305062 A1 20030320 US 2001-26651 20011218
PRAI US 2000-257308P P 20001221
US 2001-26651 A2 20011218
OS MARPAT 140:77031

LS ANSWER 12 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:892800 CAPLUS
DN 139:395950
TI Preparation of substituted pyrazines as protein kinase modulators
IN Bahr, Chris A.; Maik, Tae-Gon; Ma, Sungsoon; Feafai, Zermai Wang, Lacheng; Co, Erick Wang; Epalasyon, Sergey; Kennedy, Abigail K.; Chen, Baile; Bhat, Suresh; Dabholkar, Meel; Eun, Sung; Fung, Tessa; Duse, John M.; Peto, Cesha J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dallyapple, Lisa; Esther; Forsyth, Timothy Patrick; Euyah, Tai Phat; Mann, Grace; Mann, Larry Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
Coden: PIXKD2
DT Patent

LS ANSWER 13 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:570968 CAPLUS
DN 139:133585
TI Preparation of N-pyrasinalbenzenesulfonamides and their use in the treatment of chemokine mediated diseases such as asthma
IN Baxter, Andrew; Johnson, Timothy; Kindon, Nicholas; Roberts, Bryan; Stocke, Michael
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 175 pp.
Coden: PIXKD2
DT Patent
LA English
PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 200305893 A1 20030724 WO 2003-SE41 20030114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MW, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
EN: GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, NU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
CA 2484209 AA 20031113 CA 2003-2484209 20030502
EP 1501514 A2 20050202 EP 2003-728690 20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-377933P P 20020503
WO 2003-US13869 W 20030502
OS MARPAT 139:395950

LS ANSWER 14 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:434540 CAPLUS
DN 139:133585
TI Preparation of substituted pyrazines as protein kinase modulators
IN Bahr, Chris A.; Maik, Tae-Gon; Ma, Sungsoon; Feafai, Zermai Wang, Lacheng; Co, Erick Wang; Epalasyon, Sergey; Kennedy, Abigail K.; Chen, Baile; Bhat, Suresh; Dabholkar, Meel; Eun, Sung; Fung, Tessa; Duse, John M.; Peto, Cesha J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dallyapple, Lisa; Esther; Forsyth, Timothy Patrick; Euyah, Tai Phat; Mann, Grace; Mann, Larry Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
Coden: PIXKD2
DT Patent

LS ANSWER 15 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42250 CAPLUS
DN 139:159426
TI Synthesis, structure-activity relationship and in vitro evaluation of coelenterazine and coelenteramin derivatives as inhibitors of lipid peroxidation
IN Burcin, Magid; De Tollemanne, Catherine; Cavalier, Jean-Francois; Marchand, Celine; Dussart, Frederique; Marchand-Brynaert, Jacqueline; Rees, Jean-Francois
CS Laboratory of Cell Biology, Institut des Sciences de la Vie, Universite Catholique de Louvain, Louvain-la-Neuve, B-1340, Belg.
SO Free Radical Research (2003), 37(2), 145-159
Coden: PRXER; ISSN: 1071-5762
PB Taylor & Francis Ltd.
DI Journal
LA English
OS CASREACT 139:159426
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 16 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42253 CAPLUS
DN 139:106713
TI Preparation of heterocyclic amines for the treatment of conditions associated with GSK3
IN Berg, Stefan; Hellberg, Sven
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 62 pp.
Coden: PIXKD2
DT Patent
LA English
PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2003004475 A1 20030116 WO 2002-SE1340 20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MW, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, EG, KZ, MD, NU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
CA 2467870 AA 20030605 CA 2002-3467870 20021115
US 2003144297 A1 20030731 US 2002-398193 20021115
EP 1446387 A1 20040818 EP 2002-780507 20021115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
CA 2467870 AA 20030605 CA 2002-3467870 20021115
US 2003144297 A1 20030731 US 2002-398193 20021115
EP 1446387 A1 20040818 EP 2002-780507 20021115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
PRAI SE 2001-2438 A 20010705
WO 2002-SE1340 W 20020703
OS MARPAT 138:106713
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 17 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42250 CAPLUS
DN 139:106712
TI Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors
IN Berg, Stefan; Hellberg, Sven
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 158 pp.
Coden: PIXKD2
DT Patent
LA English
PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2003004475 A1 20030116 WO 2002-SE1339 20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MW, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
CA 2452686 AA 20030116 CA 2002-2452686 20020703
EP 1414801 A1 20040506 EP 2002-747795 20020703

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, ML, CY, AL, TR, BG, CZ, EE, SK
 HR 2002010838 A 20040713 BR 2002-10838 20020703
 JR 2005505515 T2 20050224 JP 2003-510640 20020703
 PRAI SE 2001-2439 A 20010705
 NO 2002-SE1339 W 20020703
 OS MARPAT 138-106712
 RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 18 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 2002:554265 CAPLUS
 DN 137:24205
 TI Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity
 AU Cariello, Neal P.; Wilson, John D.; Britt, Ben H.; Wedd, David J.; Burlinson, Brian; Goobar, Vijay
 CS Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
 SO Mutagenesis (2002), 17(4), 321-329
 CODEN: MUTAMX; ISSN: 0267-8357
 PB Oxford University Press
 DT Journal
 LA English
 RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 19 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 2002:487401 CAPLUS
 DN 137:47125
 TI N-heteroaryl-N'-heterocyclureas as neuropeptide Y Y5 receptor antagonists
 IN Stamford, Andrew W.; Dong, Youhao; McCombie, Stuart W.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 127 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 PAF.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2002049648 A1 20020627 WO 2001-US49302 20011217
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, IE, HU, ID, IL, IN, IS, JP, KG, KR, KP, KR, KZ, LC, LK, LR, LS, MG, MK, MU, MY, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, EG, EZ, MD, EU, IJ, TM, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
 CA 2432809 A2 20020627 CA 2001-2432809 20011217
 AU 2002034056 A5 20020701 AU 2002-34056 20011217
 EP 1343503 A1 20030107 EP 2001-985069 20011217
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 BR 2001016379 A 20030920 BR 2001-16379 20011217
 JP 2004516267 T2 20040603 JP 2002-556088 20011217
 NZ 526174 A 20041224 NZ 2001-526174 20011217
 ZA 2003004348 A 20040909 ZA 2003-4348 20030603
 NO 2003002861 A 20030821 NO 2003-2861 20030620
 PRAI US 2000-257308P P 20001221
 WO 2001-US49302 W 20011217
 OS MARPAT 137:47125

PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 PAF.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2002000199 A1 20020103 WO 2001-GB2923 20010629
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KR, KP, KR, KZ, LC, LK, LR, LS, MG, MU, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, IJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
 EP 1294360 A1 20030326 EP 2001-943685 20010629
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 JP 2004506984 T2 20040615 JP 2002-504981 20010629
 US 2004155015 A1 20040311 US 2003-312434 20030605
 PRAI GB 2000-1605 A 20000629
 WO 2001-GB2923 W 20010629
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 23 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 2002:102599 CAPLUS
 DN 136:74443
 TI Process for preparing and harvesting crystalline pharmaceutical particles
 IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
 PA Glaxo Group Ltd., UK
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 PAF.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2002000198 A1 20020103 WO 2001-GB2922 20010629
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KR, KP, KR, KZ, LC, LK, LR, LS, MG, MU, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, IJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 EP 1294359 A1 20030326 EP 2001-943684 20010629
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 JP 2004500115 T2 20040115 JP 2002-504980 20010629
 US 2003181432 A1 20030925 US 2003-312423 20030529
 PRAI GB 2000-15981 A 20000629
 WO 2001-GB2922 W 20010629
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 2001:859509 CAPLUS
 DN 136:270314

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:183584 CAPLUS
 DN 137:41243
 TI H-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-coupling drug candidates
 AU Ismail, I. M.; Dear, G. J.; Roberts, A. D.; Plum, B. S.; Ayerton, J.; Sweetman, B. C.; Bowers, G. D.
 CS Structural Identification Group, GlaxoSmithKline Research and Development, Ware, SG12 0DP, UK
 SO Xenobiotica (2002), 32(1), 29-43
 CODEN: XENOBH; ISSN: 0049-8254
 PB Taylor & Francis Ltd.
 DT Journal
 LA English
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:10467 CAPLUS
 DN 136:69823
 TI Preparation of imidazole derivatives or salts thereof and drugs containing the derivative or the salt
 IN Komoto, Yuki; Nagao, Yoshihiro; Isomae, Kazuo; Gotsuka, Mari; Takahashi, Yoshiyuki; Iwai, Fumi; Hirota, Hiroyuki; Takeda, Sunao; Kawamoto, Masaaki; Hidaka, Haruyoshi; Sato, Susumu
 PA Sanki Co., Ltd., Japan
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXKD2
 DT Patent
 LA Japanese
 PAF.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 200200648 A1 20020103 WO 2001-JP4836 20010608
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KR, KP, KR, KZ, LC, LK, LR, LS, MG, MU, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, IJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
 AU 2001064223 A5 20020108 AU 2001-64223 20010608
 CA 2410391 AA 20021128 CA 2001-2410391 20010608
 EP 1295880 A1 20030326 EP 2001-938563 20010608
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 US 2003207896 A1 20031106 US 2002-258610 20021105
 PRAI JP 2000-194024 A 20000628
 WO 2001-JP4836 W 20010608
 OS MARPAT 136:69823
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:10260 CAPLUS
 DN 136:74544
 TI Novel process for preparing and harvesting crystalline pharmaceutical particles
 IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

TI Fluorescence properties of phenolate anions of coelenteramide analogues: the light-emitter structure in aequorin bioluminescence
 AU Imai, Yuko; Shibata, Takuya; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru; Hirano, Takashi
 CS Department of Applied Physics and Chemistry, The University of Electro-Communications, Chofu, Tokyo, 182-8585, Japan
 SO Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2), 95-107
 CODEN: JPPCEJ; ISSN: 1010-6030
 PB Elsevier Science S.A.
 DT Journal
 LA English
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 2001:833264 CAPLUS
 DN 135:357945
 TI Two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine
 IN Edney, David; Kennedy, Andrew
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 11 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 PAF.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2001065674 A1 20011115 WO 2001-GB1929 20010502
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KR, KP, KR, KZ, LC, LK, LR, LS, MG, MU, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, IJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
 EP 1278721 A1 20030129 EP 2001-92571 20010502
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MZ, CY, AL, TR
 JP 2001053702 T2 20031105 JP 2001-582275 20010502
 US 2003149053 A1 20030807 US 2002-275457 20021105
 PRAI GB 2000-10971 A 20000505
 WO 2001-GB1929 W 20010502
 OS CASERACT 135:157945
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:617986 CAPLUS
 DN 135:180078
 TI Preparation of substituted arylpyrazines and their binding with CRF1 receptors
 IN Yoon, Tae-yung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Deller, Dario; Zhang, Cunyu
 PA Neurogen Corporation, USA
 SO PCT Int. Appl., 193 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 PAF.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	W 2000-GB4888	W 20001219
PI WO 2001060806	A2	20010228	WO 2001-US5264	20010216	LS ANSWER 28 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN	
PI WO 2001060806	A3	20020207			AN 2001:114448 CAPLUS	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG			DN 135:118864			
EW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG			TI Catechol derivatives of iminopyrazine and cell protection against uvb-induced mortality			
RU: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, EL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			AU Cavalier, J.-P.; Burkin, M.; Dussart, F.; Marchand, C.; Rees, J.-P.; Marchand-Brynaert, J.			
CA 2398937	A2	20010228	CA 2001-2398937	20010216	CS Unité de Chimie Organique et Medicinale, Université Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.	
EP 1255740	A3	20021113	EP 2001-910939	20010216	SO Bioorganic & Medicinal Chemistry (2001), 9(4), 1037-1044	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, EL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			PB Elsevier Science Ltd.			
US 2003018035	A1	20030123	US 2001-788315	20010216	DT Journal	
EE 20020453	A	20031215	EE 2002-453	20010216	LA English	
JP 2004500383	T2	20040108	JP 2001-560191	20010216	RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD	
BR 200108363	A	20040210	BR 2001-8363	20010216	ALL CITATIONS AVAILABLE IN THE RE FORMAT	
EP 1500653	A1	20050126	EP 2004-25531	20010216	LS ANSWER 29 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, EL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			AN 2001:78336 CAPLUS			
NZ 52044	A	20050124	BZ 2001-520484	20010216	DN 134:131548	
BR 105956	A	20050120	BG 2002-105968	20020731	TI Preparation of tricyclic compounds as allergy inhibitors, immunosuppressants, and IgE production inhibitors	
ZA 2002006103	A	20030829	ZA 2002-6103	20020731	IN Taniguchi, Norihiko; Inagaki, Masanao	
NO 2002003869	A	20020911	NO 2002-3869	20020815	PA Shionogi & Co., Ltd., Japan	
PRAI US 2000-182924P	P	20000216		SO PCT Int. Appl. 363 pp.		
US 2000-204455P	P	20000522		CODEN: PIXKD2		
EP 2001-910939	A3	20010216		DT Patent		
WO 2001-US5264	W	20010216		LA Japanese		
OS MARPAT 135:180787				PAN.CNT 3		
LS ANSWER 27 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN				PATENT NO. KIND DATE APPLICATION NO. DATE		
AN 2001:472472 CAPLUS				PI WO 2001007401 A1 20010201 WO 2000-JP4726 20000714		
DN 135:181972				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
TI Formulations of adenosine A1 agonists				AU 2000060160 A5 20010213 AU 2000-60160 20000714		
IN Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan				PRAI JP 1999-209298 A 19990723		
PA Glaxo Group Limited, UK				JP 1999-211702 A 19990727		
SO PCT Int. Appl. 32 pp.				WO 2000-JP4726 W 20000714		
DT Patent				OS MARPAT 134:131548		
LA English				RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD		
PAN.CNT 1				ALL CITATIONS AVAILABLE IN THE RE FORMAT		
PATENT NO. KIND DATE APPLICATION NO. DATE				LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN		
PI WO 2001045684 A2 20010628 WO 2000-GB4888 20001219				AN 2000:456591 CAPLUS		
WO 2001045684 A3 20020314				DN 133:79433		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG			TI Apparatus and process for preparing crystalline particles			
EP 1239800 A2 20020918 EP 2000-985631 20001219				IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				PA Glaxo Group Limited, UK		
JP 2003518042 T2 20030603 JP 2001-546423 20001219				SO PCT Int. Appl. 49 pp.		
US 2003006842 A1 20030109 US 2002-168196 20020618				CODEN: PIXKD2		
PRAI GB 1999-30079 A 19991220				DT Patent		
RE.CNT 1				LA English		
PATENT NO. KIND DATE APPLICATION NO. DATE				PAN.CNT 1		
PI WO 200038811 A1 20000706 WO 1999-GB4368 19991222				PATENT NO. KIND DATE APPLICATION NO. DATE		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG				PI WO 20001007401 A1 20010201 WO 2000-JP4726 20000714		
US 6402430 B1 20021119 US 1999-348948 19990707				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
CA 2356697 AA 20000763 CA 1999-2356697 19991222				PRAI JP 1999-209298 A 19990723		
BR 9916587 A 20010925 BR 1999-16587 19991222				JP 1999-211702 A 19990727		
EP 1144065 A1 20011017 EP 1999-962413 19991222				WO 2000-JP4726 W 20000714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, IE, SI, FI				OS MARPAT 134:131548		
TR 20010184 T2 20011022 TR 2001-200101845 19991222				RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD		
JP 2002253205 T2 20021008 JP 2000-590755 19991222				ALL CITATIONS AVAILABLE IN THE RE FORMAT		
JP 3588050 B2 20041110				LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN		
NZ 512400 A 20030228 NZ 1999-512400 19991222				AN 2000:145691 CAPLUS		
AU 755980 B2 20030501 AU 2000-18771 19991222				DN 133:79433		
NO 2001003039 A 20010823 NO 2001-3039 20010619				TI Preparation of pyrazines as anticonvulsants		
ZA 2001005070 A 20020920 ZA 2001-5070 20010620				IN Cox, Brian; Healy, Mark Patrick; Wild, Deborah		
PRAI GB 1998-20721 A 19981224				PA Glaxo Group Limited, UK		
WO 1999-GB4368 W 19991222				SO PCT Int. Appl. 40 pp.		
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD				CODEN: PIXKD2		
ALL CITATIONS AVAILABLE IN THE RE FORMAT				DT Patent		
LS ANSWER 31 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN				LA English		
AN 2000:325409 CAPLUS				PAN.CNT 1		
DN 132:334474				PATENT NO. KIND DATE APPLICATION NO. DATE		
TI Preparation of spiroindolines as Y5 receptor antagonists				PI WO 1998-107835P P 199801110		
IN Gao, Ying-duo; Macniss, Douglas J.; Yang, Lihua; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki				US 1999-436120 A3 19991108		
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.				US 1999-26447 W 19991108		
SO PCT Int. Appl. 130 pp.				US 2000-656698 A3 20000907		
CODEN: PIXKD2				US 2001-896940 A3 20010629		
DT Patent				US 2002-228250 A3 20020826		
LA English				OS MARPAT 132:134474		
PAN.CNT 1				RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD		
PATENT NO. KIND DATE APPLICATION NO. DATE				ALL CITATIONS AVAILABLE IN THE RE FORMAT		
PI WO 2000027845 A1 20000518 WO 1999-US26447 19991108				LS ANSWER 32 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, CG, CI, OM, GA, GN, GW, ML, MR, NE, SN, TD, TG				AN 2000:161266 CAPLUS		
CA 2350714 AA 20000518 CA 1999-2350714 19991108				DN 132:194395		
US 6191160 B1 20010220 US 2000-436120 19991108				TI Preparation of pyrazines as anticonvulsants		
EP 1129089 A1 20010005 EP 1999-971808 19991108				IN Cox, Brian; Healy, Mark Patrick; Wild, Deborah		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJJ, CF, IE, SI, LT, LV, FI, RO				PA Glaxo Group Limited, UK		
TR 200100603 T2 20010723 TR 2001-200100603 19990826				SO PCT Int. Appl. 40 pp.		
JP 20020523499 T2 20020730 JP 2000-567518 19990826				CODEN: PIXKD2		
TW 429255 B 20010411 TW 1999-8814723 19990827				DT Patent		
US 6503909 B1 20030107 US 2001-762295 20010208				LA English		
US 2003022904 A1 20030130 US 2002-216399 20020812				PAN.CNT 1		
PRAI GB 1998-18881 A 19980828				PATENT NO. KIND DATE APPLICATION NO. DATE		
WO 1999-EP6248 W 19990826				PI WO 1998-107835P P 199801110		
US 6495559 B2 20021217 2002012695 A1 20010208				PRAI JP 1999-209298 A 19990723		
US 6638942 B1 2003010280 US 2002-228250 20020826				JP 2000-590755 A1 20000907		
US 2004040401 A1 20040401 US 2003-624414 20030721				DN 131:129097		
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD				TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors		
ALL CITATIONS AVAILABLE IN THE RE FORMAT				IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko		
LS ANSWER 33 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN				PA Shionogi & Co., Ltd., Japan		
AN 1999-1405256 CAPLUS				SO PCT Int. Appl. 258 pp.		
DN 131:129097				CODEN: PIXKD2		
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors				DT Patent		
IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko				LA Japanese		
PA Shionogi & Co., Ltd., Japan				PAN.CNT 1		
SO PCT Int. Appl. 258 pp.				PATENT NO. KIND DATE APPLICATION NO. DATE		
CODEN: PIXKD2				PI WO 1998-107835P P 199801110		
DT Patent				PRAI JP 1999-209298 A 19990723		
LA English				JP 2000-590755 A1 20000907		
PAN.CNT 1				DN 131:129097		
PATENT NO. KIND DATE APPLICATION NO. DATE				TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors		
PI WO 1998-107835P P 199801110				IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko		
PRAI JP 1999-209298 A 19990723				PA Shionogi & Co., Ltd., Japan		
JP 2000-590755 A1 20000907				SO PCT Int. Appl. 258 pp.		
DN 131:129097				CODEN: PIXKD2		
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors				DT Patent		
IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko				LA Japanese		
PA Shionogi & Co., Ltd., Japan				PAN.CNT 1		
SO PCT Int. Appl. 258 pp.				PATENT NO. KIND DATE APPLICATION NO. DATE		
CODEN: PIXKD2				PI WO 1998-107835P P 199801110		
DT Patent				PRAI JP 1999-209298 A 19990723		
LA English				JP 2000-590755 A1 20000907		
PAN.CNT 1				DN 131:129097		
PATENT NO. KIND DATE APPLICATION NO. DATE				TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors		
PI WO 1998-107835P P 199801110				IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko		
PRAI JP 1999-209298 A 19990723				PA Shionogi & Co., Ltd., Japan		
JP 2000-590755 A1 20000907				SO PCT Int. Appl. 258 pp.		
DN 131:129097				CODEN: PIXKD2		
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors				DT Patent		
IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko				LA Japanese		
PA Shionogi & Co., Ltd., Japan				PAN.CNT 1		
SO PCT Int. Appl. 258 pp.				PATENT NO. KIND DATE APPLICATION NO. DATE		
CODEN: PIXKD2				PI WO 1998-107835P P 199801110		
DT Patent				PRAI JP 1999-209298 A 19990723		
LA English				JP 2000-590755 A1 20000907		
PAN.CNT 1				DN 131:129097		
PATENT NO. KIND DATE APPLICATION NO. DATE				TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors		
PI WO 1998-107835P P 199801110				IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiko		
PRAI JP 1999-209298 A 19990723				PA Shionogi & Co., Ltd., Japan		
JP 2000-590755 A1 20000907				SO PCT Int. Appl. 258 pp.		
DN 131:129097				CODEN: PIXKD2		
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors				DT Patent		

reaction.
 AU Turck, A.; Ple, N.; Trobey, D.; Ndzi, B.; Queguiner, G.
 CS Lab. Chim. Org. Pines Heterocyclics, INSA, Mt. St. Aignan, 76131, Fr.
 SO Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
 CODEN: JHETCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 117:171380

LS ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:35307 CAPLUS
 DN 96:35307
 TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl) ureas
 IN Miesel, John L.
 PA Eli Lilly and Co., USA
 SO U.S., 15 pp. Cont.in-part of U.S. Ser. No. 881,300, abandoned.
 CODEN: USXKAM

DT Patent
 LA English
 OS CASREACT 117:171380

PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 4293552 A 19811006 US 1979-62393 19790731
 PRAI US 1979-881300 A2 19780227

LS ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1980:620777 CAPLUS
 DN 93:220777
 TI Substituted 2-aminopyrazines
 IN Barnett, Charles J.; Demick, Thomas L.; Hoying, Richard C.
 PA Eli Lilly and Co., USA
 SO U.S., 11 pp.
 CODEN: USXKAM

DT Patent
 LA English
 PANT. CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 4211870 A 19800708 US 1979-27630 19790406
 DE 8001442 A 19801007 DK 1980-1442 19800402
 FI 8001056 A 19801007 FI 1980-1056 19800402
 AU 8057102 A1 19801009 AU 1980-57102 19800402
 FR 2453159 A1 19801031 FR 1980-7457 19800402
 BE 8002079 A 19801125 BE 1980-2079 19800402
 ES 490287 A1 19801516 ES 1980-490287 19800402
 CS 215055 P 19802730 CS 1980-2293 19800402
 CA 1157860 A1 19831129 CA 1980-349061 19800402
 BE 882608 A1 19801003 BE 1980-9771 19800403
 EP 10144 A1 19801029 EP 1980-301085 19800403

R: DE, GB, NL, SE
 GB 2046751 A 19801119 GB 1980-11363 19800403
 DE 2046751 A1 19801119 DE 1980-11363 19800403
 DD 19800403 C 19801082 DD 1980-220207 19800403
 ZA 8002005 A 19801125 ZA 1980-2005 19800403
 RU 36151 O 19830928 RU 1980-317 19800403
 SU 623989 A3 198020530 SU 1980-2902455 19800404
 RU 79384 P 19802625 RO 1980-100722 19800404
 JP 651414723 A2 19801105 JP 1980-45114 19800405
 PRAI US 1979-27630 A 19790406

LS ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:540598 CAPLUS
 DN 91:140598
 TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas

DT Patent
 LA English
 PANT. CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 4211870 A 19800708 US 1979-27630 19790406
 DE 8001442 A 19801007 DK 1980-1442 19800402
 FI 8001056 A 19801007 FI 1980-1056 19800402
 AU 8057102 A1 19801009 AU 1980-57102 19800402
 FR 2453159 A1 19801031 FR 1980-7457 19800402
 BE 8002079 A 19801125 BE 1980-2079 19800402
 ES 490287 A1 19801516 ES 1980-490287 19800402
 CS 215055 P 19802730 CS 1980-2293 19800402
 CA 1157860 A1 19831129 CA 1980-349061 19800402
 BE 882608 A1 19801003 BE 1980-9771 19800403
 EP 10144 A1 19801029 EP 1980-301085 19800403

R: DE, GB, NL, SE
 GB 2046751 A 19801119 GB 1980-11363 19800403
 DE 2046751 A1 19801119 DE 1980-11363 19800403
 DD 19800403 C 19801082 DD 1980-220207 19800403
 ZA 8002005 A 19801125 ZA 1980-2005 19800403
 RU 36151 O 19830928 RU 1980-317 19800403
 SU 623989 A3 198020530 SU 1980-2902455 19800404
 RU 79384 P 19802625 RO 1980-100722 19800404
 JP 651414723 A2 19801105 JP 1980-45114 19800405
 PRAI US 1979-27630 A 19790406

LS ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:152238 CAPLUS
 DN 90:152238
 TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
 IN Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Norman Henry
 PA Eli Lilly and Co., USA
 SO Ger. Offen., 86 pp.
 CODEN: GWXKX

DT Patent
 LA German
 PANT. CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
 PI DE 2826893 A1 19790118 DE 1978-2826893 19780619
 DE 4133954 A 19790109 US 1977-819639 19770727
 IL 54928 A1 19820228 IL 1978-54928 19780615
 IL 64263 A1 19820930 IL 1978-64263 19780615
 FR 2398738 A1 19790223 FR 1978-18187 19780616
 FR 2398738 B1 19810508

IN 149912 A 19820529 IN 1978-C4666 19780616
 BE 868228 A1 19781219 BE 1978-8936 19780619
 GB 2001053 A 19790124 GB 1978-27260 19780619

AU 516505 B2 19810604 AU 1978-37249 19780619

AU 7837249 A1 19800103

GB 2066806 A 19810715 GB 1980-19107 19780619

GB 2066806 B2 19820818

AT 7804456 A 19810115 AT 1978-4456 19780619

AT 367046 B 19820525

CA 1129861 A1 19800817 CA 1978-305703 19780619

HU 23227 O 19820830 HU 1978-E1793 19780620

HU 180726 B 19830429

RO 78069 P 19830803 RO 1978-94410 19780620

HU 19827 O 19840130 HU 1982-1470 19780620

DK 1980336 B 19810709

DK 7802793 A 19781223 DK 1978-2793 19780621

SE 7801727 A 19781233 SE 1978-7127 19780621

SE 7806678 A 19781230 NL 1978-6678 19780621

BR 7803939 A 19790230 BR 1978-3039 19780621

ZA 7803553 A 19800227 ZA 1978-3553 19780621

CS 198104 A 19800530 CS 1978-4095 19780621

CS 198105 P 19800530 CS 1978-8519 19780621

CS 198106 P 19800530 CS 1978-8520 19780621

SU 799662 D 19810123 SU 1978-2628947 19780621

CH 638500 A 19830930 CH 1978-6770 19780621

JP 54009288 A2 19790124 JP 1978-76343 19780622

ES 471057 A1 19800116 ES 1978-471057 19780622

LS ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:509584 CAPLUS
 DN 89:109584

TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas

IN Miesel, John Louis

PA Eli Lilly and Co., USA

SO U.S., 15 pp.
 CODEN: USXKAM

DT Patent
 LA English
 PANT. CNT 4

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 4083972 A 19780411 US 1976-742948 19761118
 US 3984137 A 19761005 US 1975-595504 19750714

AT 7705635 A 19800615 AT 1977-5635 19770729

AT 368000 B 19810126

PRAI US 1974-507492 A2 19740919

US 1975-595504 A3 19750714

AT 1975-7146 A 19750917

LS ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:50924 CAPLUS
 DN 88:50924

TI 1-Benzoyl-3-pyrazinylureas

PA Eli Lilly and Co., USA

SO Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKKMF

DT Patent
 LA Japanese
 PANT. CNT 4

PATENT NO. KIND DATE APPLICATION NO. DATE

PI JP 52010205 A2 19770126 JP 1976-1426 19760101
 PRAI US 1975-595904 A 19750714

LS ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:421468 CAPLUS
 DN 85:21468

TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas

IN Miesel, John L.

PA Eli Lilly and Co., USA

SO Ger. Offen., 70 pp.
 CODEN: GWXKX

DT Patent
 LA English
 OS CASREACT 117:171380

IN Miesel, John L.

PA Eli Lilly and Co., USA

SO U.S., 19 pp.

CODEN: USXKAM

DT Patent

LA English

PANT. CNT 4

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 4160834 A 19790710 US 1977-861733 19771219
 AT 7705635 A 19800615 AT 1977-5635 19770729

AT 360800 B 19810126

PRAI US 1974-507492 A2 19740919

US 1975-595504 A2 19750714

US 1977-775813 A2 19770309

AT 1975-7146 A 19750917

LS ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:152238 CAPLUS
 DN 90:152238

TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas

IN Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Norman Henry

PA Eli Lilly and Co., USA

SO Ger. Offen., 86 pp.
 CODEN: GWXKX

DT Patent

LA German

PANT. CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI DE 2826893 A1 19790118 DE 1978-2826893 19780619
 DE 4133954 A 19790109 US 1977-819639 19770727

DE 2001053 B2 19800228

IL 54928 A1 19820228 IL 1978-54928 19780615

IL 64263 A1 19820930 IL 1978-64263 19780615

FR 2398738 A1 19790223 FR 1978-18187 19780616

FR 2398738 B1 19810508

IN 149912 A 19820529 IN 1978-C4666 19780616

BE 868228 A1 19781219 BE 1978-8936 19780619

GB 2001053 A 19790124 GB 1978-27260 19780619

AU 516505 B2 19810604 AU 1978-37249 19780619

AU 7837249 A1 19800103 AU 1978-37249 19780619

DE 19700118 A 19780103 DE 1975-106877 19750915

DE 2541116 C2 19800518

IN 142286 A 19770619 IN 1975-CA1744 19750910

BE 833288 A1 19760311 BE 1975-106877 19750911

IL 48092 A1 19790312 IL 1975-48092 19750912

AU 7584045 A1 19770324 AU 1975-84845 19750915

GB 1521714 A 19780816 GB 1975-37933 19750916

CA 1070308 A1 19800122 CA 1975-235561 19750916

NL 7510901 A 19760323 NL 1975-10901 19750917

ZA 7505945 A 19770427 ZA 1975-5945 19750917

AT 7507146 A 19771015 AT 1975-7146 19750917

CS 195710 A 19800229 CS 1975-6298 19750917

DK 7504195 A 19760320 DK 1975-4195 19750918

SE 7510474 A 19760322 SE 1975-10474 19750918

SE 426066 B 19812062

SE 426066 C 19830317

PL 103954 P 19790321 PL 1975-107527 19750918

PL 103954 P 19811010 PL 1975-103470 19750918

CH 617192 A 19800115 CH 1975-12147 19750918

HU 19446 O 19810320 HU 1975-E1646 19750918

HU 172000 P 19810320

JP 51056490 A 19760518 JP 1975-114226 19750919

BR 2506073 A 19760803 BR 1975-6073 19750919

FR 2299327 A1 19760827 FR 1975-28772 19750919

FR 2299327 B1 19780407

DK 123341 C 19761212 DK 1975-188451 19750919

ES 441124 A1 19770616 ES 1975-441124 19750919

DD 120762 C 19771207 DD 1975-196898 19750919

SU 662011 D 19790505 SU 1975-2171811 19750919

SU 660566 D 19790430 SU 1976-2380308 19760709

AT 7705635 A 19800615 AT 1977-5635 19770729

AT 360800 B 19810126

SE 7006517 A 19780602 SE 1978-6517 19780602

SE 420042 B 19810914

SE 420042 C 19820107

PRAI US 1974-507492 A 19740919

AT 1975-7146 A 19750917

LS ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1973:537092 CAPLUS

DN 79:137092

TI Pteridines. XXIX. Unequivocal route to 2,4-diamino-6-substituted

pteridines

COST IN U.S. DOLLARS
FULL ESTIMATED COSTSINCE FILE
ENTRY
TOTAL
SESSION
56.55 218.95

=> D HIS

(FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005)

FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005
L1 STRUCTURE UPLOADEDL2 QUB L1
L3 50 S L2
L4 978 S L2 SSS FULLFILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005
51 S L4

=> D LS 11, 12, 14, 18-51 IBIB ABS HITSTR

LS ANSWER 11 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004-20338 CAPLUS

DOCUMENT NUMBER: 140:77031

TITLE: N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5

receptor antagonists

INVENTOR(S): Stamford, Andrew; Dong, Youhao; McCombie, Stuart W.;

Wu, Yusheng

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.

Ser. No. 26,651.

CODEN: USXKCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006068	A1	200404108	US 2002-177345	20020620
US 2003055062	A1	20030320	US 2001-26651	20011218
PRIORITY APPLN. INFO.:			US 2000-257300P	P 20001221
			US 2001-26651	A2 20011218

OTHER SOURCE(S): MARPAT 140:77031

GI

ONLY PRIOR
ART HITS FROM 15
SELECTED -THOSE
RECORDS
ARE
DISPLAYED
IBIB, ABS,
HITSTR.


II

AB R2NHCONMe2IR1 [I; R = fluorophenyl; R1 = alkanoyl, alkylsulfonyl, pyridinyl(carbonyl), etc.; Z = pyridine-, pyrazine-, or pyrimidine-2,5-diyil, etc.; Z1 = e.g., piperidine-4,1-diyil] were prepared. Thus, 3,5-P2C6H3B(CH3)2 was condensed with 2-bromo-5-nitropyridine and the reduced product condensed with COCl2 and N-methyl-1-(2-pyridinyl)piperidine-4-amine to give II. Data for biol. activity of I were given. Pharmaceutical composition comprising the compound I is claimed.

IT 438584-80-6 438584-81-7 438584-82-8P
438584-83-9 438584-84-0F 438584-96-4PRL: PAT (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists)






RN 438584 CAPPLUS

CN 4-Piperidinamine, 1-acetyl-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl-1-(9CI) (CA INDEX NAME)



RN 438584-81-7 CAPPLUS

CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

RN 438584-82-8 CAPPLUS
CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)RN 438584-83-9 CAPPLUS
CN 4-Piperidinamine, 1-(cyclopropylcarbonyl)-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)RN 438584-84-0 CAPPLUS
CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)RN 438584-96-4 CAPPLUS
CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl]-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)LS ANSWER 12 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003-892800 CAPLUS
DOCUMENT NUMBER: 139:395950
TITLE: Preparation of substituted pyrazines as protein kinase modulators
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sungchon; Tesfai, Zerom; Wang, Langcheng; Co, Erick Wang; Epshteyn,

Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larissa; Asaad, Neel Kumar; Tsang, Teze H.; Nuss, John M.; Peto, Cesiba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abulkader; Schnapp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa; Escher, Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy; Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 468 pp., CODEN: PIKWD3

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003093297 A2 20031113 WO 2003-US13869 20030502

WO 2003093297 A3 20040701

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VE, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IS, IT, LU, NC, NL, PT, RO, SE, SI, SP, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

CA 2484209 A1 20031113 CA 2003-2484209 20030502

EP 1501514 A2 20050202 EP 2003-728690 20030502


R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, US 2002-377833P P 20020503
PRIORITY APPLN. INFO.: NO 2003-US13869 W 20030502
OTHER SOURCE(S): MARPAT 139:395950
GI

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH, A, CO, CS, C(NR6), R7 (when A = R7, E does not exist); R8 = H, NO2, CN, etc.; R9 = (un)substituted 5-7 membered heterocyclyl] E (NR8R9, NR8R2, NR8R4, etc.; R6 = H, alkyl, R9 = H, heterocyclyl, etc.; NR8R3) (un)substituted 5-7 membered heterocyclyl; W = 5-10 membered arylene, 5-10 membered heterocyclyl; R = (un)substituted alkylene, O(CH2)2-10, etc.; Y = H, alkyl, aryl, etc., with previous] for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is

IT 535934-78-29, 5-[(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-16-16,
 5-[(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-24-16,
 cis-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol 535935-76-35, 5-[(2,4-dichlorophenyl)-3,6-diethyl-
 (cis-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine 535936-05-28, Benzyl cis-3-[(5-(2,4-dichlorophenyl)-3,6-
 diethylpyrazin-2-yl)amino]-4-ethoxypyrrrolidin-1-carboxylate 535936-07-39, 5-[(2,4-dichlorophenyl)-N-(cis-4-ethoxypyrrrolidin-3-
 yl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrrrolidin-1-carboxylate 535936-26-65, Benzyl (3R,4S)-3-[(5-(2,4-dichlorophenyl)-3,6-
 diethylpyrazin-2-yl)amino]-4-ethoxypyrrrolidin-3-yl 535936-27-76,
 5-[(2,4-dichlorophenyl)-N-(3R,4S)-4-ethoxypyrrrolidin-3-yl]-3,6-diethylpyrazin-2-amine 535936-29-96, Benzyl (3R,4S)-3-[(5-(2,4-
 dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrrolidin-1-carboxylate 535936-30-2P,
 5-[(2-chloro-4-methoxyphenyl)-N-(3R,4S)-4-ethoxypyrrrolidin-3-yl]-3,6-diethylpyrazin-2-amine 535936-45-98 535936-32-06,
 Methyl (2-methoxy-2,3-dichlorophenyl)-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrrrolidin-2-carboxylate 535936-41-56, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrrolidin-1-carboxylate 535936-41-56, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrrolidin-1-carboxylate 535936-42-66,
 5-[(2-chloro-4-methoxyphenyl)-N-(3R,4S)-4-ethoxypyrrrolidin-3-yl]-3,6-diethylpyrazin-2-amine 535936-45-98 535936-32-06,
 Methyl (2-methoxy-2,3-dichlorophenyl)-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrrrolidin-2-carboxylate 535936-41-56, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrrolidin-1-carboxylate 535936-41-56, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrrolidin-1-carboxylate 535936-42-66,
 (drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine deriva. as CPI receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535934-78-2 CAPLUS


CN Pyrazinamine, 5-[(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-24-1 CAPLUS

CN 2-Naphthalenol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-1,2,3,4-tetrahydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535935-76-3 CAPLUS


CN Pyrazinamine, 5-[(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-6-methoxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-06-2 CAPLUS


CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)



RN 535936-29-9 CAPLUS

CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535936-30-2 CAPLUS

CN Pyrazinamine, 5-[(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-36-8 CAPLUS

CN 1-Pyrrolidinocarboxylic acid, 3-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RE 535936-39-1 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 3-[(5-[2-chloro-4-methoxyphenyl]-3,6-diethylpyrazinyl)amino]-4-hydroxy- phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-41-5 CAPLUS
CN 1-Pyridin-2-ylmethoxyacrylic acid, 3-[(5-(2-chloro-4-methoxyphenyl))-3,6-diethylpyrazinyl]amino)-4-(2-fluoroethoxy)-, phenylmethyl ester, (3R,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-42-6 CAPLUS
CN Pyrazinamine, 5-(3-chloro-4-methoxyphenyl)-N-[(3R,4S)-4-ethoxy-3-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535936-45-9 CAPLUS
CN Pyrazinamidine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-32-0 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino)-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry




IT 535934-30-6F. 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine **535934-31-7F**. 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-((1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535934-32-8F**. 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-((1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine

ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methoxypyrazine-2-carboxamide
535934-44-49. 3-(2,4-Dichlorophenyl)-6-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(methylthio)pyrazine-2-carboxamide
EL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses);
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CBP1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)


RU 535934-30-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RU 535934-31-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RU 535934-32-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(1-methylethoxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RU 535934-36-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1S,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RU 535934-39-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1S,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RU 535934-40-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1S,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RU 535934-43-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RU 535934-44-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl)-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RU 535934-45-3 CAPLUS
CN Pyrazinamine, N-((1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl)-5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-46-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-propenyl)oxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-48-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-propenyl)oxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-47-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-methoxyethoxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-49-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-((1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-50-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-propoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-53-3 CAPLUS
CN Carbamic acid, dimethyl-, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




BN 535934-51-1 CAPLUS
CN Ethanol, 2-[(1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




BN 535934-54-4 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-56-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dieethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-58-8 CAPLUS
CN 1H-Inden-2-ol, 1-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-57-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-60-2 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-61-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-64-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-63-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-67-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-60-0 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-((1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-71-5 CAPLUS
 CN Pyrazinamine, 5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 535934-74-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 535934-75-9 CAPLUS
 CN Pyrazinamine, N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 535934-79-3 CAPLUS
 CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535934-83-9 CAPLUS
 CN 1-isoquinolinamine, N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 535934-87-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 535934-90-4 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(4,6-dimethyl-2-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 535934-91-9 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-4-benzofuranyl)- (9CI) (CA INDEX NAME)




RN 535934-93-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-5-methyl-4-benzofuranyl)- (9CI) (CA INDEX NAME)




RN 535934-98-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535934-99-7 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535935-02-5 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzothiopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-10-5 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535935-13-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-05-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-06-9 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-5-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)




RN 535935-09-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535935-20-7 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-21-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535935-25-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

RN 535935-29-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4S,5E)-4,5,6,7-tetrahydrobenzo(b)thien-4-yl]- (9CI) (CA INDEX NAME)




RN 535935-32-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4E,5E)-4,5,6,7-tetrahydro-5-methylbenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-26-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-, 3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-33-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-methylbenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-35-4 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydrobenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-37-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydrobenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 535935-42-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-43-4 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-44-5 CAPLUS
 CN Pyrazinamine, N-(3,4-dihydro-2H-1-benzopyran-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




BN 535935-53-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-propylbenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




BN 535935-54-7 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-propylbenzo(b)thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




BN 535935-58-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535935-59-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535935-60-5 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(1-methylethoxy)-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




BN 535935-64-9 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-8-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




BN 535935-67-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-6-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




BN 535935-79-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-5-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



BN 535935-82-1 CAPLUS
 CN 5H-Cyclopenta(b)pyridin-7-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 535935-87-6 CAPLUS
 SH-Cyclopenta[b]pyridin-5-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 535935-93-4 CAPLUS
 SH-Cyclopenta[b]pyridin-7-amine, N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]-6-ethyl-, 6,7-dihydro-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-99-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-00-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-08-4 CAPLUS
 CN 3-Pyrrolidinamine, 1-acetyl-N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-09-5 CAPLUS
 CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(1-oxopropyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-10-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, methyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-11-9 CAPLUS
 CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(methylsulfonyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-14-2 CAPLUS
 CN 3-Pyrrolidinamine, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-N,N-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-15-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, 1-methylethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535936-16-4 CAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-N-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 535936-17-5 CAPLUS
CN Morpholine, 4-(((3R,4S)-3-((5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino)-4-ethoxy-1-pyrrolidinyl)carbonyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-18-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino)-4-ethoxy-, 2-fluoroethyl ester, (3E,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-28-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino)-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-44-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino)-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino)-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-51-7 CAPLUS
CN Pyrazinamine, N-((3R,4S)-4-ethoxytetrahydro-3-furanyl)-3,6-diethyl-5-(4-methoxy-2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-31-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino)-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-37-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethylpyrazinyl)amino)-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-40-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-((5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino)-4-ethoxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-57-3 CAPLUS
CN Pyrazinamine, N-((3R,4R)-4-ethoxytetrahydro-3-furanyl)-3,6-diethyl-5-(4-methoxy-2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-67-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-((3R,4R)-tetrahydro-4-methoxy-3-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-69-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-((3R,4R)-4-ethoxytetrahydro-3-furanyl)-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-76-6 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-84-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 535937-81-6 CAPLUS
 CN Pyrazinamine, 3,6-dicyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-84-9 CAPLUS
 CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-87-2 CAPLUS
 CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-90-7 CAPLUS
 CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-94-1 CAPLUS
 CN Pyrazinamine, 6-cyclopropyl-5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-92-9 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-96-3 CAPLUS
 CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-98-5 CAPIUS
 CN Pyrazinamine, 3-cyclopropyl-5-[(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-01-3 CAPIUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-00-2 CAPIUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-03-5 CAPIUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-08-0 CAPIUS
 CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-N2-ethyl-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-12-6 CAPIUS
 CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-2,3-dihydro-N2-(2-methoxyethyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-10-4 CAPIUS
 CN Acetanilide, N-[(1R,2R)-1-[(3,6-dicyclopropyl)pyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535938-14-8 CAPIUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-16-0 CAPLUS
CN Pyrazinamine, 5-[(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-36-4 CAPLUS
CN Pyrazincarboxylic acid, 6-[(1R,2S)-2-(acetylxy)-2,3-dihydro-1H-inden-1-yl]amino-3-(2,4-dichlorophenyl)-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-47-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethenyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-49-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetoxy)-4-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 535938-55-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-59-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-62-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-51-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetoxy)-4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-53-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)




RN 535938-65-9 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-68-2 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-70-6 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(1-oxopropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-73-9 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(1-oxopropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-76-3 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-[(1-oxopropyl)amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-79-5 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-(acetylamino)-4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-82-0 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(ethylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-85-3 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(propylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-87-5 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-88-6 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-90-0 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-92-3 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-94-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-96-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-98-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(1-piperidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-00-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-02-7 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(1-oxaproxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-03-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(1-oxaproxy)-, 2-(dimethylamino)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-06-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, 2-(1-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-07-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(1H-imidazol-1-yl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-09-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(methylamino)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-11-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-aminoethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-13-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-hydroxyethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-15-2 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-2-methoxyethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-17-4 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-2-(2-oxo-1(2H)-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-18-5 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-2-(2-oxo-1(2H)-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-20-9 CAPLUS
CN 2-Pyrrolidinone, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-22-1 CAPLUS
CN 2-Pyrrolidinone, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-1-methyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-24-3 CAPLUS
CN 2-Pyrrolidinone, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-1-(phenylmethyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-28-7 CAPLUS
CN 2-Pyrrolidinone, 4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-3-(2-fluoroethoxy)-1-methyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-30-1 CAPLUS
CN 2-Pyrrolidinone, 4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-3-(2-fluoroethoxy)-1-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535939-32-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 535939-34-5 CAPLUS
 CN Furo[2,3-b]pyridine-2-carboxylic acid, 3-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]-2,3-dihydro-, ethyl ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-36-7 CAPLUS
 CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-(ethoxymethyl)-2,3-dihydro-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-38-9 CAPLUS
 CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-ethyl-2,3-dihydro-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




1-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-45-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-47-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-49-2 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 535939-40-3 CAPLUS
 CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2,3-dihydro-2-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-42-9 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-43-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI)

Absolute stereochemistry.



RN 535939-51-6 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-53-8 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 535939-55-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-57-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl)pyrazinyl)amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-59-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl)pyrazinyl)amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-61-8 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-((1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-63-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-((1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-65-2 CAPLUS
 CN Acetic acid, hydroxy-, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-67-4 CAPLUS
 CN Acetic acid, hydroxy-, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-68-5 CAPLUS
 CN Acetic acid, methoxy-, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-70-9 CAPLUS
 CN Acetic acid, methoxy-, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-72-1 CAPLUS
 CN Pyrazinamine, N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-76-5 CAPLUS
 CN Glycine, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-74-3 CAPLUS
 CN Pyrazinamine, N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-78-7 CAPLUS
 CN Glycine, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-80-1 CAPLUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2,3-dihydro-2-(2-(methylamino)ethoxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-84-5 CAPLUS
 CN Glycine, N-methyl-, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-82-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(2-(methylamino)ethoxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-86-7 CAPLUS
 CN Glycine, N-methyl-, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-88-9 CAPIUS
 CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-(dimethylamino)ethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-92-5 CAPIUS
 CN Glycine, N,N-dimethyl-, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-90-3 CAPIUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-(2-(dimethylamino)ethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-93-6 CAPIUS
 CN Glycine, N,N-dimethyl-, (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-95-8 CAPIUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, methylcarbamate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-02-4 CAPIUS
 CN 1H-Inden-2-ol, 1-[(5-(4-chloro-2-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-.., acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-97-0 CAPIUS
 CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-07-9 CAPIUS
 CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-09-1 CAPLUS
CN 3-Furanol, 4-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-11-5 CAPLUS
CN 3-Furanol, 4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-13-7 CAPLUS
CN 3-Furanol, 4-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-15-9 CAPLUS
CN 3-Furanol, 4-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-16-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-propoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-20-6 CAPLUS
CN 2(3H)-Furanone, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-24-0 CAPLUS
CN 2(3H)-Furanone, 4-(acetoxy)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]dihydro-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-22-0 CAPLUS
CN 2(3H)-Furanone, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxydihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535940-26-2 CAPLUS
CN 2(3H)-Furanone, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]dihydro-4-(1-oxopropoxy)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




BN 535940-20-4 CAPLUS
 CN 2(2H)-Puracaine, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]dihydro-4-propoxy-, (3S,4R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-32-0 CAPLUS
 CN 1H-Inden-1,2-dimino, N1-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N2-ethyl-1,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-30-8 CAPLUS
 CN 2(2H)-Puracaine, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-34-2 CAPLUS
 CN Acetamide, N-[(1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-36-4 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethoxy- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-40-0 CAPLUS
 CN Pyrazinacarbonamide, 3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-ethyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



BN 535940-38-6 CAPLUS
 CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




BN 535940-42-2 CAPLUS
 CN Pyrazinacarbonamide, 3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxy- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RU 535940-44-4 CAPLUS
 CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 535940-46-6P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)pyrazin-2-amine
 535940-48-8P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methoxypyrazin-2-amine
 535940-50-2P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methoxypyrazin-2-amine
 535940-52-4P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-(methylthio)pyrazin-2-amine
 535940-54-6P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methylthio)pyrazin-2-amine
 535940-56-8P, 5-(2,4-Dichlorophenyl)-3-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino-5-methoxypyrazine-2-carboxamide
 535940-58-0P, 5-(2,4-Dichlorophenyl)-3-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino-5-methoxypyrazine-2-carboxamide
 535940-60-4P, 6-(2,4-Dichlorophenyl)-3-((1R,2S)-2-ethoxy-2,3-

dihydro-1H-inden-1-yl)amino-5-(methylthio)pyrazine-2-carboxamide
 535940-61-56, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)pyrazine-2,3-diamine
 535940-63-76, 6-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-N'-N''-dimethylpyrazine-2,3,5-triamine
 535940-65-96, 3-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-5-ethyl-N'-methylpyrazine-2,6-diamine
 535940-71-76, trans-N-((2-Chloro-4-methoxyphenyl)-3,6-dichlorypyrazin-2-yl)-6-ethyl-7-dihydro-5H-cyclopenta[b]pyridin-7-amine
 RL: ARG (Analytical reagent use); BUV (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses);
 (drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)


RN 535940-46-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-48-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-50-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-52-4 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-54-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-56-8 CAPLUS
 CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino-5-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-50-0 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-61-5 CAPLUS
CN 2,3-Pyrazinediamine, 5-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-N3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-60-4 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-63-7 CAPLUS
CN Pyrazinetriamine, 6-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N3,N5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-65-9 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(preparation of substituted aryl pyrazine derivs. as CRP1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)
RN 535936-43-7 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-1,6-diethylpyrazinyl)amino]-4-ethoxy- (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-34-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 535934-29-3P, (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-35-1P , (1S,2R)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-37-3P, (1S,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl 3,6-nitrobenzoate 535934-38-4P, (1S,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-41-9P, (1R,2R)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-42-0P, (1R,2R)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-52-2P 535934-55-5P, (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-59-9P (1S,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-62-4P, (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-65-7P, (1R,2S)-1-[(5-(2-Chloro-4-(dimethylaminomethyl)phenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535934-69-1P , trans-1-[(5-(2-Chloro-4-(dimethylaminomethyl)phenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535935-19-4P , diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535935-57-0P, (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535936-03-9P, Benzyl trans-3-[(5-(2,4-dichlorophenyl)-3,6-


RN 535940-71-7 CAPLUS
CN 5H-Cyclopenta[b]pyriden-7-amine, N-(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)-6-ethyl-6,7-dihydro-, (6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 535936-43-7, (3R,4S)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrolidine-1-carboxylate 535938-34-2, Methyl 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxypyrazine-2-carboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)




IT 535936-43-7, (3R,4S)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrolidine-1-carboxylate 535938-34-2, Methyl 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxypyrazine-2-carboxylate

diethylpyrazin-2-yl]amino)-4-hydroxypyrrolidine-1-carboxylate
 535936-04-09. Benzyl *cis*-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol-4-[(4-nitrobenzoyl)carbonyl]pyrrolidine-1-carboxylate
 535936-05-18. Benzyl *cis*-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate
 535936-25-59. Benzyl (1R,4S)-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]pyrrolidine-1-carboxylate
 535936-49-39. *trans*-4-[(3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino]tetrahydrofuran-3-ol-535936-53-99
 , *cis*-4-[(3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino]tetrahydrofuran-3-yl-4-nitrobenzoate
 535936-55-18. *cis*-4-[(3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino]tetrahydrofuran-3-ol-535936-65-35. *cis*-4-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol-535937-53-2P. (1R,2S)-1-[(6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-58-7P
 , (1R,2S)-1-[(3-Cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-61-2P
 , (1R,2S)-1-[(6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-63-4P
 , (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-65-6P
 , (1R,2S)-1-[(6-Cyclopropyl-5-(2-methylaminocarbonyl)-4-methylpyridin-3-yl)-3-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol-535937-67-6P
 , (1R,2S)-1-[(6-Cyclopropyl-5-(2-methylaminocarbonyl)-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-69-0P
 , (1R,2S)-1-[(3-Cyclopropyl-5-(6-(methylaminocarbonyl)-4-methylpyridin-3-yl)-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-72-5P
 , (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-75-8P
 , (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535937-78-1P
 , (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-1-yl-1-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino-5-bromo-3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino pyrazine-2-carboxylate
 535938-28-4P. Methyl 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino pyrazine-2-carboxylate
 535938-30-0P. Ethyl 3-(2,4-dichlorophenyl)-6-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino-5-methoxypyrazine-2-carboxylate
 535938-42-2P. Methyl 3-[(2,4-Dichlorophenyl)-6-methoxypyrazin-2-yl]amino-2,3-dihydro-1H-inden-2-ol-535938-43-3P
 , (1R,2S)-1-[(3-Bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol-535938-45-5P
 , (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)


RN 535934-29-3 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-35-1 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-37-3 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, 4-nitrobenzoate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-39-4 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-41-9 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, 4-nitrobenzoate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-42-0 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 535934-52-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-[(1,1-dimethylethyl)dimethylsilyloxy]ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-55-5 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-59-9 CAPLUS
 CN 1H-Inden-2-ol, 1-[(3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-62-4 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-65-7 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-69-1 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(4-methyl-3-pyridinyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535935-19-4 CAPLUS
 CN 2-Naphthalenol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-1,2,3,4-tetrahydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-05-1 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-25-5 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-49-3 CAPLUS
 CN 3-Furanol, 4-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]tetrahydro-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-57-0 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-03-9 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-hydroxy-, phenylmethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-04-0 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-[(4-nitrobenzoyl)oxy]-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-53-9 CAPLUS
 CN 3-Furanol, 4-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]tetrahydro-, 4-nitrobenzoate (ester), (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-55-1 CAPLUS
 CN 3-Furanol, 4-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-65-3 CAPLUS
 CN 3-Furanol, 4-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




BN 535937-53-2 CAPLUS
 CN 1H-Inden-2-ol, 1-[(3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-61-2 CAPLUS
 CN 1H-Inden-2-ol, 1-[(6-cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-55-4 CAPLUS
 CN 1H-Inden-2-ol, 1-[(6-cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-59-7 CAPLUS
 CN 1H-Inden-2-ol, 1-[(3-cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-63-4 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-65-6 CAPLUS
 CN 1H-Inden-2-ol, 1-[(6-cyclopropyl-5-(dimethylamino)-4-methyl-3-pyridinyl)-3-ethylpyrazinylamino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-67-8 CAPLUS
 CN 1H-Inden-2-ol, 1-[(3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-69-0 CAPLUS
 CN 1H-Inden-2-ol, 1-[(3-cyclopropyl-5-(6-(dimethylamino)-4-methyl-3-pyridinyl)-6-ethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-72-5 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 535937-75-8 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-6-ethyl-3-methylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



BN 535937-78-1 CAPLUS
 CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3-ethyl-6-methylpyrazinyl)amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



BN 535938-04-6 CAPLUS
 CN Pyrazinamine, N-[(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IE, SI, LT, LV, PL, RO, MX, CY, AL, TR
 ER 2001016379 A 20030930 BR 2001-16379
 JP 2002-550988 T2 20040503 2001217
 NZ 526174 A 20041224 NZ 2001-526174 2001217
 ZA 2003004348 A 20040909 ZA 2003-4348 20030603
 NO 2003002861 A 20030821 NO 2003-2861 20030620
 PRIORITY APPLN. INFO.: US 2000-257308P P 20001221
 WO 2001-US49302 W 20011217

OTHER SOURCE(S): MARPAT 137:47125

AB RENZOCOMEZIR: (I; R = fluorophenyl; R1 = alkanoyle, alkylsulfonyl, pyridinyl(carbonyl), etc.; Z = pyridine-, pyrazine-, or pyrimidine-2,5-diy, etc.; Z1 = e.g., piperidine-4,1-diy) were prepared. Thus, 3,5-F2C6H3(CH)2 was condensed with 2-bromo-5-nitropyridine and the reduced product condensed with COCl2 and N-methyl-1-(2-pyridinyl)pyridine-4-amine to give I (R = C6H7-3,5, R1 = 2-pyridinyl, Z = pyridine-2,5-diy, Z1 = piperidine-4,1-diy). Data for biol. activity of I were given.


IT 438584-80-6 438584-81-76 438584-82-8P

438584-83-9 438584-84-0P

EL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (n-heteroaryl-N-heterocyclureas as neuropeptide Y Y5 receptor antagonists)


RN 438584-80-6 CAPLUS

CN 4-Piperidinamine, 1-acetyl-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-81-7 CAPLUS

CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 438584-82-8 CAPLUS

CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

AUTHOR(S): candidates
 Ismail, I. M.; Dear, G. J.; Roberts, A. D.; Plumb, R. S.; Myrton, J.; Sweetman, B. C.; Bowers, G. D.
 CORPORATE SOURCE: Structural Identification Group, GlaxoSmithKline Research and Development, Ware, SG12 0DP, UK
 SOURCE: Yenobiotica (2002), 32(1), 29-43
 CODEN: XENOBH; ISSN: 0049-8254
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The urinary metabolites of the anti-convulsant compound 4-amino-1-(2,6-difluorophenyl)-1H-1,2,3-triazolo[4,5-c]pyridine hydrochloride (GI265080) obtained following a single oral dose to man have been detected and quantified relative to each other using 1H-NMR spectroscopy. The human urinary metabolites of GI265080 were isolated using semipreparative HPLC and unequivocally characterized using 1H-NMR spectroscopy, two-dimensional heteronuclear NMR spectroscopy and mass spectrometry. The assignments of the N-(5)-oxide and the N-(5)-O-glucuronide metabolites of GI265080 were further confirmed by independent synthesis. The urinary metabolites obtained following single oral doses to dog and rat have also been isolated and characterized. The human urinary metabolites of GI265080 comprise the N-(5)-oxide, the quaternary N-(5)-glucuronide, the 7-hydroxy glucuronide and a glucuronide conjugate of the N-(5)-oxide. The N-(5)-O-glucuronide conjugate is a novel species in human metabolism and is a significant route of elimination of GI265080 in man. The urinary metabolites of the potential anti-convulsant GW773293 (6-amino-3-(2,3,5-trichlorophenyl)pyrazin-2-ylamine) obtained following a single oral dose to man have been isolated and characterized. The formation of a novel N-O-glucuronide was also observed and was shown to constitute a significant route of elimination of GW773293 in man.


IT 212778-82-0, GW 273293 437651-94-0 437651-96-2
 437651-97-3 438553-55-0, GW 412446
 EL: PKT (Pharmacokinetics); BIOL (Biological study)
 (N-O-glucuronidation, a major human metabolic pathway in elimination of two novel anti-convulsant drug candidates)

RN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 437651-94-0 CAPLUS
 CN Pyrazinium, 2,6-diamino-1-(β-D-glucopyranuronosyl oxy)-3-(2,3,5-trichlorophenyl)-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 438584-83-9 CAPLUS

CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl- (9CI) (CA INDEX NAME)




RN 438584-84-0 CAPLUS

CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-96-4 CAPLUS

CN 4-Piperidinamine, N-[(5-(2,5-difluorophenyl)pyrazinyl)amino]carbonyl-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:193594 CAPLUS


DOCUMENT NUMBER: 137:41243

TITLE: N-O Glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug



RN 437651-96-2 CAPLUS


CN 2(H)-Pyrazinone, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 437651-97-3 CAPLUS


CN β-D-Glucopyranosiduronic acid, 3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438553-55-0 CAPLUS

CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)-, 1-oxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 200210467 CAPLUS

DOCUMENT NUMBER: 136:69823

TITLE: Preparation of imidazole derivatives or salts thereof and drugs containing the derivatives or the salts

INVENTOR(S): Kommo, Fujiko; Nagao, Yoshihiro; Isomae, Kazuo; Gitsuka, Mari; Takahashi, Yoshiyuki; Ishii, Fumiyo; Hirota, Hiroyuki; Takeda, Sumio; Kawamoto, Noriyuki; Honda, Haruyoshi; Sato, Susumu

PATENT ASSIGNEE(S): Sep Co., Ltd., Japan

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000468	A1	20020103	WO 2001-JP4836	20010608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001064223	A5	20020108	AU 2001-64223	20010608
CA 2410391	AA	20021128	CA 2001-2410391	20010608
EP 1295880	A1	20030326	EP 2001-938563	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR				
US 2003207896	A1	20031106	US 2002-258610	20021105
PRIORITY APPLN. INFO.: JP 2000-194024	JP 2000-194024	A 20000628		
		WO 2001-JP4836	W 20010608	

OTHER SOURCE(S): MARPAT 136:69823
GI



I




II

AB Title compds. [I], R1, R2 each independently = aryl, heteroaryl; A, X1, X2 each independently = O, S, NH, SO2, CH2, NHCOR; R3, R4, R5 each independently = H, alkyl, NH2, alkoxy, Cl; n = 1, 2, 3, 4; n = 0, 1, 2, 3, 4 and salts are prepared and formulation discussed. Title compds. I exhibit excellent inhibitory activities against the production of NO and IL-6 and are useful in the prevention or treatment of diseases resulting from over-development of NO and IL-6. Thus, the title compound II is prepared and tested as an antiinflammatory in male ICR mouse with inhibitory activity on 35.5% for 3 mg/kg dosage.

IT 385413-98-98
EL: PAF (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. or salts thereof and drugs containing derivs. or salts)

EN 385413-98-9 CAPLUS

CN Pyrazine, 2-(2-(4-(2-(4-(1H-imidazol-1-ylmethyl)phenoxy)ethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 200210260 CAPLUS

DOCUMENT NUMBER: 136:74644

TITLE: Novel process for preparing and harvesting crystalline pharmaceutical particles

INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

ACCESSION NUMBER: 200210295 CAPLUS
DOCUMENT NUMBER: 136:74643
TITLE: Process for preparing and harvesting crystalline pharmaceutical particles

INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2002000198 A1 20020103 WO 2001-GB2922 20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294350 A1 20030326 EP 2001-943685 20010629

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR

JP 2004500984 T2 20040115 JP 2002-504981 20010629

US 2004050984 A1 20040311 US 2003-312434 20030606

PRIORITY APPLN. INFO.: GB 2000-16040 A 20000629

WO 2001-GB2923 W 20010629

AB The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly pharmaceutical or carrier substances of a size suitable for inhalation therapy. Fluticasone propionate was dissolved in hot acetone and then allowed to cool to ambient temperature. A flow

cell was then charged with a 4:1 mixture of water and acetone. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20 mL/min. Pump 2 (containing chilled water) was set at 80 mL/min. An ultrasound probe was then delivered at 70-75 W of power. When the ultrasound probe and both pumps were turned on a rapid onset of crystallization occurred. The slurry output was collected in a flask and concentrated in vacuo until all of the acetone had been removed, leaving only aqueous slurry. The contents of the flask were then freeze dried overnight to give a free flowing fine dry white powder. No sieving or deggregation of the particles by passing them through a screen was necessary.

IT 212778-82-0

EL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(process for preparing and harvesting crystalline pharmaceutical particles for inhalation therapy)

RN 212778-82-0 CAPLUS

CN 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.


Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group. At position 6, there is another chlorine atom.

Chemical structure of 2,6-Pyrazinidamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME): It features a central pyrazine ring with a chlorine atom at position 1 and an amino group at position 4. At position 2, there is a 2,3,5-trichlorophenyl group.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:855909 CAPLUS


DOCUMENT NUMBER: 136:270314
TITLE: Fluorescence properties of phenolate anions of coelenteramide analogues: the light-emitter structure in aequorin bioluminescence
AUTHOR(S): Imai, Yuko; Shibata, Takuwa; Maki, Shojiro; Niwa, Haruki; Hashi, Mamoru; Hirano, Takashi
CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Chofu, Tokyo, 182-8585, Japan
SOURCE: Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2), 95-107
PUBLISHER: Elsevier Science S.A.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To elucidate the ionic structure of the excited state of light-emitter coelenteramide in aequorin bioluminescence, the fluorescence properties of phenolate anions of coelenteramide analogs were investigated. Fluorescence of phenolate anion in non-polar solvents was observed by electronic excitation of a 1:1 hydrogen-bonded complex of a coelenteramide analog with a hydrogen-bond donor mol. such as *n*-butyramine. In polar solvents, the phenolate anion was directly generated using a base, and its fluorescence was studied. These results confirm that the singlet-excited state of phenolate anion of coelenteramide has an intramol. CT character, and that its fluorescence emission wavelength changes depending upon solvent polarity. The fluoro-substituent effect on the fluorescent property of phenolate anions was also clarified to help in explaining the bioluminescent property of fluorinated semi-synthetic aequorin. These results consistently support the assignment that the phenolate anion is the ionic structure of the excited light-emitter in BFP during AQ bioluminescence.

IT 404939-52-2P 404939-55-5P
RL: CPS (Chemical process); PER (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)


(fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence)
RN 404939-52-2 CAPLUS
CN Octanamide, *N*-(5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl)- (9CI) (CA INDEX NAME)




RN 404939-55-5 CAPLUS
CN Octanamide, *N*-(5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl)- (9CI) (CA INDEX NAME)



IT 404939-62-4 404939-66-8
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
(fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence in relation to)
RN 404939-62-4 CAPLUS
CN Octanamide, *N*-(5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl)- ion(1-) (9CI) (CA INDEX NAME)



RN 404939-66-8 CAPLUS
CN Octanamide, *N*-(5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl)- ion(1-) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:853364 CAPLUS

DOCUMENT NUMBER: 135:357945
TITLE: Two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine
INVENTOR(S): Edney, Dean David; Kennedy, Andrew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085674	A1	20011115	WO 2001-GB1929	20010502
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RU: GH, GM, KR, SD, SL, SZ, TZ, US, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1270721	A1	20030129	EP 2001-925711	20010502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, MK, CY, AL, TR				
JP 2002357702	T2	20031115	JP 2001-582275	20010502
US 2002149053	A1	20030807	US 2002-375457	20021105
US 6003646	B2	20041012		

PRIORITY APPLN. INFO.: GB 2000-10971 A 20000505
WO 2001-GB1929 W 20010502

OTHER SOURCE(S): CASREACT 135:357945
AB A process for the preparation of 2-[cyano(2,3,5-trichlorophenyl)methyl]amino)acetamide or its acid-addition salts (e.g., the hydrobromide; I) comprises:

(i) reaction of an acid salt of aminocetamide (e.g., aminocetamide dihydrobromide) with a source of cyanide (e.g., KCN); and (ii) reaction of the product of step (i) with 2,3,5-trichlorobenzaldehyde.

2,6-Diamino-3-(2,3,5-trichlorophenyl)pyrazine is prepared by the intramol.


cyclocondensation reaction and oxidation of I or its acid-addition salts in the presence of a methanolic lithium hydroxide solution

IT 212778-02-0P

RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine)

RN 212778-02-0 CAPLUS
CN 2,6-Pyrazinediimine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:617986 CAPLUS

DOCUMENT NUMBER: 135:180787
TITLE: Preparation of substituted arylpyrazines and their binding with CRF1 receptors
INVENTOR(S): Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lambaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060806	A2	20010823	WO 2001-USS264	20010216
WO 2001060806	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RU: GH, GM, KR, SD, SL, SZ, TZ, US, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2390837	AA	20010823	CA 2001-2398937	20010216
EP 1255746	A2	20021113	EP 2001-910939	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003018035	A1	20030123	US 2001-788315	20010216
EE 200200453	A	20031215	EE 2002-453	20010216
JP 2004500383	T2	20040108	JP 2001-560191	20010216
BR 2001008363	A	20040210	BR 2001-8363	20010216
EP 1500563	A1	20050126	EP 2004-25531	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 520494	A	20050324	NZ 2001-520494	20010216
BG 106968	A	20030430	BG 2002-106968	20020731
ZA 2002006103	A	20030820	ZA 2002-6103	20020731
NO 2002003869	A	20020911	NO 2002-3869	20020815

PRIORITY APPLN. INFO.: MARPAT 135:180787
GI



AB Arylpyrazine compds. I [Ar = substituted Ph, naphthyl, heterocycl, R1, R3 = H, halo, cyano, NO2, etc.; R2 = halo, amino, alkyl, etc.], including arylpyrazines that can bind with high affinity and high selectivity to

102(a)


CRP1 receptors, including human CRP1 receptors, were prepared. E.g., N-(1-ethylpropyl)-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine was prepared by reaction of 2-chloro-3,6-dimethylpyrazine with 1-ethylpropylamine, followed by bromination and reaction with 2,4-dimethoxybenzoic acid.

IT 355834-56-9P 355835-13-1P

EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of substituted arylpyrazines and their binding with CRP1 receptors)


RN 355834-56-9 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 355835-13-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



IT 355834-36-5P 355834-37-6F 355834-38-7P

355834-40-1P 355834-41-2P 355834-44-5P

355834-45-6P 355834-46-7F 355834-48-9P

355834-49-0P 355834-50-3F 355834-52-5P

355834-53-6P 355834-54-7F 355834-57-0P

355834-58-1P 355834-59-2F 355834-60-5P

355834-63-2P 355834-64-3F 355834-65-4P

355834-67-3P 355834-68-3F 355834-69-1P

355834-70-7P 355834-71-8F 355834-72-9P

355834-73-0P 355834-74-1F 355834-75-2P

355834-76-3P 355834-77-4F 355834-78-5P

355834-79-6P 355834-84-3F 355834-85-4P

355834-86-5P 355834-87-6F 355834-88-7P

355834-89-8P 355834-90-1F 355834-91-2P

355834-92-3P 355834-93-4F 355834-94-5P

355834-95-6P 355834-96-7F 355834-97-8P

355834-98-9P 355834-99-0F 355835-00-6P

355835-01-7P 355835-02-8F 355835-03-9P

355835-04-0P 355835-05-1F 355835-06-2P

355835-07-3F 355835-08-4F 355835-09-5P

355835-10-8F 355835-11-9F 355835-12-0P

355835-14-2F 355835-15-3F 355835-16-4P

355835-17-5F 355835-18-6F 355835-19-7P

355835-20-0F 355835-21-1F 355835-22-2P

355835-23-3F 355835-24-4F 355835-25-5P

355835-26-6F 355835-27-7F 355835-30-2P

355835-31-3F 355835-33-5F 355835-35-7P

355835-37-9F 355835-38-0F 355835-39-1P

355835-40-4F 355835-41-5F 355835-42-6P

355835-43-7F 355835-44-8F 355835-45-9P

355835-46-0F 355835-47-1F 355835-48-2P

355835-49-3F 355835-50-6F 355835-51-7P

355835-52-8F 355835-53-9F 355835-54-0P

355835-55-1F 355835-56-2F 355835-57-3P

355835-58-4F 355835-59-5F 355835-60-8P

355835-61-9F 355835-62-0F 355835-63-1P

355835-64-2F 355835-66-4F 355835-70-0P

355835-71-1F 355835-72-2F 355835-73-3P

355835-74-4F 355835-75-5F 355835-76-6P

355835-77-7F 355835-78-8F 355835-79-9P

355835-80-2F 355835-81-3F 355835-82-4P

355835-83-5F 355835-84-6F 355835-85-7P

355835-86-8F 355835-87-9F 355835-88-0P

355835-89-1F 355835-90-2F 355835-91-3P

355835-92-6F 355835-93-7F 355835-94-8P

355835-95-9F 355835-96-0F 355835-97-1P

355835-98-2F 355835-99-3F 355836-00-9P

355836-02-1F 355836-03-2F 355836-04-3P

355836-39-4F 355836-41-6F 355836-42-9P

355836-46-3F 355836-47-4F 355836-48-5P

355836-50-9F 355836-52-1F 355836-54-3P

355836-56-5F 355836-57-6F 355836-58-7P

355836-59-8F 355836-60-1F 355836-61-2P

355836-62-3F 355836-63-4F 355836-64-5P

355836-65-6F 355836-66-7F 355836-67-8P

355836-68-9F 355836-69-0F 355836-70-3P

355836-71-4F 355836-72-5F 355836-73-6P

355836-74-7F 355836-75-8F 355836-76-9P

355836-77-0F 355836-78-1F 355836-80-5P

355836-81-6F 355836-82-7F 355836-83-8P

355836-84-9F 355836-85-0F 355836-86-1P

355836-87-2F 355836-88-3F 355836-89-4P

355836-90-7F 355836-91-8F 355836-92-9P

355836-93-0F 355836-94-1F 355836-95-2P

355836-96-3F 355836-97-4F 355836-98-5P

355836-99-6F 355837-00-2F 355837-01-3P

355837-03-5F 355837-04-6F 355837-06-8P

355837-07-9F 355837-08-0F 355837-09-1P

355837-10-4F 355837-12-6F 355837-14-8P


355837-15-5F 355837-24-0F 355837-25-1P

355839-04-0P

EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of substituted arylpyrazines and their binding with CRP1 receptors)


RN 355834-36-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-44-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-45-6 CAPLUS

CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-46-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-48-9 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

RN 355834-49-1 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-(methoxymethyl)propyl)-3,6- dimethyl- (9CI) (CA INDEX NAME)

RN 355834-50-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-(methoxymethyl)propyl)-3,6- dimethyl- (9CI) (CA INDEX NAME)




RN 355834-49-0 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-54-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-50-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-57-0 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 355834-52-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-58-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-53-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-59-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methoxymethyl)propyl- (9CI) (CA INDEX NAME)




RN 355834-60-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-64-9 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-61-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-65-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-62-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-66-1 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-63-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methoxymethyl)propyl- (9CI) (CA INDEX NAME)




RN 355834-67-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methoxymethyl)propyl- (9CI) (CA INDEX NAME)




RN 355834-68-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-72-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-69-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-73-0 CAPLUS
CN Pyrazinamine, 5-(4-dimethoxyphenyl)-3,6-diethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355834-70-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-74-1 CAPLUS
CN Pyrazinamine, 5-(4-dimethoxyphenyl)-3,6-diethyl-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-71-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-75-2 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-76-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-84-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-77-4 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-85-4 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355834-78-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-86-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-79-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-87-6 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-88-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-89-8 CAPLUS
CN Pyrazine, 2-(1-ethylpropoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-90-1 CAPLUS
CN Pyrazine, 2-(cyclopropylmethoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-95-6 CAPLUS
CN Pyrazine, 2-(cyclopropylphenylmethoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-96-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((2-propylcyclohexyl)oxy)- (9CI) (CA INDEX NAME)




RN 355834-97-8 CAPLUS
CN Pyrazine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355834-98-9 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-91-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(dicyclopropylmethoxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-92-3 CAPLUS
CN Pyrazine, 2-(1-cyclohexylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-93-4 CAPLUS
CN Pyrazine, 2-(1-cyclopentylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-94-5 CAPLUS
CN Pyrazine, 2-(1-cyclopentylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-99-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-00-6 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-methoxymethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-01-7 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 355835-02-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-05-1 CAPLUS
 CN Pyrazinamine, N-butyl-5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-triethyl- (9CI) (CA INDEX NAME)




RN 355835-03-9 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-06-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-04-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 355835-07-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-(1-methoxymethyl)- (9CI) (CA INDEX NAME)




RN 355835-08-4 CAPLUS
 CN Pyrazinamine, N-(cyclopropylmethyl)-5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355835-11-9 CAPLUS
 CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 355835-09-5 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl)-N,3,6-triethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355835-12-0 CAPLUS
 CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-10-8 CAPLUS
 CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-14-2 CAPLUS
 CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-15-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 355835-16-4 CAPLUS
CN Pyrazinamine, 3-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-20-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 355835-17-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-iodo- (9CI) (CA INDEX NAME)




RN 355835-21-1 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355835-18-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355835-22-2 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355835-19-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355835-23-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355835-24-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355835-30-2 CAPLUS
CN 1-Butanol, 2-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino- (9CI) (CA INDEX NAME)




RN 355835-25-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355835-31-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-26-6 CAPLUS
CN Pyrazinamine, 2-ethyl-3-(1-ethylpropoxy)-5-methoxy-6-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-33-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-27-7 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 355835-35-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-37-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-41-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methoxy-1-methoxymethyl)ethyl- (9CI) (CA INDEX NAME)




RN 355835-38-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-42-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(2-methoxy-1-methoxymethyl)ethyl- (9CI) (CA INDEX NAME)




RN 355835-39-1 CAPLUS
CN 2(1H)-Pyridinone, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 355835-43-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(2-methoxy-1-methoxymethyl)ethyl- (9CI) (CA INDEX NAME)




RN 355835-40-4 CAPLUS
CN 2(1H)-Pyridinone, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)





RN 355835-44-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethyl-6-[3-(4-morpholinyl)ethoxy]phenyl)-3,6-diethyl-N-(2-methoxy-1-methoxymethyl)ethyl- (9CI) (CA INDEX NAME)




RN 355835-45-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)





RN 355835-49-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4,6-bis(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-50-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(dicyclopropylmethyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355835-51-7 CAPLUS
CN 1,2-Propanediamine, N2-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-52-8 CAPLUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,4-dimethoxyphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)







RN 355835-53-9 CAPIUS
CN Pyrazinamine, 5-(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-57-3 CAPIUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 355835-54-0 CAPIUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355835-58-4 CAPIUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-ethoxy- (9CI) (CA INDEX NAME)




RN 355835-55-1 CAPIUS
CN 1,2-Ethanediamine, N-(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)-N',N'-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355835-59-5 CAPIUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 355835-56-2 CAPIUS
CN Pyrazinamine, 5-(2,4-dieethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-60-6 CAPIUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(difluoromethoxy)- (9CI) (CA INDEX NAME)




RN 355835-61-9 CAPIUS
CN Phenol, 4-(3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355835-66-4 CAPIUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 355835-62-0 CAPIUS
CN Pyrazinamine, 5-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-70-0 CAPIUS
CN Pyrazinamine, 5-(4-methyl-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-63-1 CAPIUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(1-methylethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-71-1 CAPIUS
CN Pyrazine, 5-(4-ethyl-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355835-64-2 CAPIUS
CN Pyrazinamine, 5-[2,4-bis(1-methylethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-72-2 CAPIUS
CN Pyrazine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methoxymethyl)ethoxy- (9CI) (CA INDEX NAME)




RN 355835-73-3 CAPIUS
 CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-74-4 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 355835-75-5 CAPIUS
 CN Pyrazine, 2-(1-cyclohexylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-76-6 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-5-[(4-methoxycyclohexyl)oxy]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-77-7 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)




RN 355835-78-8 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 355835-79-9 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-3-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



CN 1-Butanamine, 2-[(5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl)oxy]- (9CI)
 (CA INDEX NAME)




RN 355835-80-2 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(3-piperidinyl)oxy)- (9CI) (CA INDEX NAME)



RN 355835-81-3 CAPIUS
 CN Cyclohexanamine, 4-[(5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 355835-82-4 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355835-83-5 CAPIUS
 CN 1-Propanamine, 2-[(5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl)oxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 355835-84-6 CAPIUS
 CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-3-pyrrolidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 355835-88-0 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(3-pyrrolidinyl) - (9CI)
(CA INDEX NAME)




RN 355835-91-5 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(4-pyridinyl) - (9CI)
(CA INDEX NAME)




RN 355835-89-1 CAPLUS
CN Butanoic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl)oxy] - , ethyl ester (9CI) (CA INDEX NAME)




RN 355835-90-4 CAPLUS
CN Pentanoic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl)oxy] - , ethyl ester (9CI) (CA INDEX NAME)




RN 355835-92-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4,6-dimethylphenyl) - (9CI) (CA INDEX NAME)



RN 355835-93-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(1-ethylpropoxy)-3,6-dimethyl - (9CI)
(CA INDEX NAME)




RN 355835-94-8 CAPLUS
CN Phenol, 2-[(3,6-diethyl-5-(1-ethylpropoxy)pyrazinyl)-3,5-dimethyl - (9CI)
(CA INDEX NAME)




RN 355835-95-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-ethylpropoxy) - (9CI)
(CA INDEX NAME)


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 355835-99-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-00-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-02-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-(2-methoxy-4-(trifluoromethyl)phenyl) - (9CI) (CA INDEX NAME)




RN 355836-03-2 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-(2-methoxy-4-(trifluoromethoxy)phenyl) - (9CI) (CA INDEX NAME)




RN 355835-98-2 CAPLUS







RN 355836-04-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 355836-39-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-41-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-42-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(trifluoromethyl)phenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-46-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-47-4 CAPLUS
CN Pyrazinamine, 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-48-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl(1,1'-biphenyl)-4-yl)- (9CI) (CA INDEX NAME)





RN 355836-50-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-methylbutoxy)- (9CI) (CA INDEX NAME)




RN 355836-52-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(2-methyl-1-(1-methylethyl)propoxy)-6-(2-methyl-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)



RN 355836-58-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-59-8 CAPLUS
CN Carbonodithioic acid, O-[3-chloro-4-(5-((1-ethylpropyl)amino)-6-methoxy-3-methylpyrazinyl)phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-56-5 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-(2-methyl-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355836-57-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-59-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-60-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4,6-bis(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 355836-61-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 355836-62-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-66-7 CAPLUS
CN Pyrazinamine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




RN 355836-63-4 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-67-8 CAPLUS
CN Pyrazinamine, 5-(4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-64-5 CAPLUS
CN Carbonodithioic acid, O-(3-chloro-4-[3,6-diethyl-5-(1-ethylpropyl)amino]phenyl) S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-68-9 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2,6-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-65-6 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-3-ethoxy-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-69-0 CAPLUS
CN Pyrazinamine, 5-(2,6-dimethoxy-4-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-70-3 CAPLUS
CN Pyrazinamine, 2-(2-chloro-4-methoxyphenyl)-3,6-diethyl-5-(2-methyl-1-(1-methylethyl)propoxy)- (9CI) (CA INDEX NAME)




RN 355836-74-7 CAPLUS
CN Pyrazinamine, 2-(2-chloro-4-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-71-4 CAPLUS
CN Benzenemethanol, 4-(3-ethyl-5-((1-ethylpropyl)amino)-6-methoxypyrazinyl)-3,5-dimethoxy-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 355836-75-8 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-methylethoxy)phenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-72-5 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-76-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-73-6 CAPLUS
CN Pyrazinamine, 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-77-0 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-78-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




BN 355836-83-8 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2-(1-methylethoxy)phenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-80-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




BN 355836-84-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




BN 355836-81-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




BN 355836-85-0 CAPLUS
CN Pyrazine, 2-(2-chloro-4-(trifluoromethyl)phenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




BN 355836-82-7 CAPLUS
CN Pyrazinamine, 2,5-dimethyl-3-(2-ethyl-4-methoxyphenyl)-6-(1-propylbutoxy)- (9CI) (CA INDEX NAME)




BN 355836-86-1 CAPLUS
CN Pyrazinamine, 2-(1-fluoroethyl)-5-(4-(1-ethylpropoxy)phenyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-87-2 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(2-methoxyethoxy)phenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-91-8 CAPLUS
CN Pyrazinamine, 5-(4-(1-fluoroethoxy)-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




BN 355836-88-3 CAPLUS
CN Pyrazinamine, 5-(4-(difluoromethoxy)-2-methoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-92-9 CAPLUS
CN Pyrazine, 2-(2-chloro-4-propoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355836-89-4 CAPLUS
CN Pyrazinamine, 5-(4-(dimethylamino)methyl)-2-methoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-93-0 CAPLUS
CN Pyrazine, 2-(2-chloro-4-(cyclopropylmethoxy)phenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355836-90-7 CAPLUS
CN Benzenemethanol, 4-[5-((1-ethylpropyl)amino)-6-methoxy-3-methylpyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)







BN 355836-95-2 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-4-(1-methylethoxy)phenyl)-6-methyl- (9CI) (CA INDEX NAME)




BN 355836-99-6 CAPLUS
CN Phenol, 4-[(1-ethylpropyl)amino]-5-(2-methoxypyrazinyl)-3-methoxy- (9CI) (CA INDEX NAME)




BN 355836-96-3 CAPLUS
CN Pyrazine, 2-[(1,1-dimethylethyl)dimethylsilyloxy]-3-(1-methylethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355837-00-2 CAPLUS
CN Pyrazinamine, 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-4-(1-methylethoxy)phenyl)- (9CI) (CA INDEX NAME)




BN 355836-97-4 CAPLUS
CN Pyrazine, 2-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355837-01-3 CAPLUS
CN Phenol, 4-[(3,6-diethyl-5-(2-methyl-1-(1-methylethyl)propoxy)pyrazinyl)-3-ethyl- (9CI) (CA INDEX NAME)




BN 355836-98-5 CAPLUS
CN Pyrazine, 2-(2,6-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355837-03-5 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(2-methyl-1-(1-methylethyl)propoxy)-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




BN 355837-04-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




BN 355837-09-1 CAPLUS
CN Pyrazine, 2-[(1,1-dimethylethyl)dimethylsilyloxy]-2-ethoxyphenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




BN 355837-06-8 CAPLUS
CN Pyrazinamine, 6-chloro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




BN 355837-10-4 CAPLUS
CN Formamide, 2-(6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazinyl)- (9CI) (CA INDEX NAME)




BN 355837-07-9 CAPLUS
CN Pyrazine, 2-(4-butoxy-2-chlorophenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




BN 355837-12-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-(1-methylethoxy)-4-propoxypyhenyl]- (9CI) (CA INDEX NAME)




BN 355837-08-0 CAPLUS
CN Pyrazinamine, N-(1-ethylbutyl)-6-methoxy-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




BN 355837-14-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-23-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355837-24-0 CAPLUS
CN Pyrazine, 2-(4-chloro-2,6-dimethoxyphenyl)-3-ethyl-5-(1-ethylpropoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-25-1 CAPLUS
CN Pyrazinamine, 5-ethyl-3-(1-ethylpropoxy)-6-(2-methoxy-5-(trifluoromethoxy)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 355839-94-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




IT 355836-12-36 355836-19-0F 355836-20-3P
355836-27-0F 355836-28-1F 355836-29-2P
355836-34-9F 355836-35-0F 355836-36-1P
355836-37-2P
RL: RCT (Reactant); SPP (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted arylpyrazines and their binding with CRP1 receptors)
RN 355836-12-3 CAPLUS
CN 2(1H)-Pyridinone, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-hydroxy- (9CI) (CA INDEX NAME)



RN 355836-19-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-20-3 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-27-0 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-


(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355836-28-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)-, 4-oxide (9CI) (CA INDEX NAME)




RN 355836-36-1 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)



RN 355836-39-2 CAPLUS
CN Pyrazinamine, 6-chloro-3-ethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)



RN 355836-37-2 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)



RN 355836-34-9 CAPLUS
CN Pyrazinamine, 6-methoxy-N-[(4-methoxyphenyl)methyl]-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

LS ANSWER 27 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 2001:472472 CAPLUS

DOCUMENT NUMBER: 135:81972
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

----- ----- ----- ----- -----

WO 2001045684 A2 20010628 WO 2000-GB4898 20000129


WO 2001045684 A3 20020314

W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GR, GD, GE, GH, GM, HR,

HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LX, LR, LS, LT,

LJ, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,



RN 355836-35-0 CAPLUS
CN Pyrazinamine, 3-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

SD, SE, SG, SI, SK, SL, TJ, TM, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BV, EG, EZ, MG, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IS, LU, MC, NL, PT, SE, BF, BJ,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1239880 A2 20020918 EP 2000-985631 20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT,
IE, SI, LT, LV, PL, RO, MX, CY, AL, IE
JP 2003518042 T2 20030603 JP 2001-546423 20001219
US 2003008842 A1 20030109 US 2002-168196 20020518
PRIORITY APPLN. INFO.: GB 1999-30079 A 19991220
WO 2000-GB4888 W 20001219


AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and a sodium channel blocker. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3R,5R)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-[6-(4-chlorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropanoic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluorocaniline and deprotection.

IT 212778-82-0 259828-60-9

EL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (formulations of adenosine A1 agonists)


RN 212778-82-0 CAPLUS

CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 259828-60-9 CAPLUS

CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




LS ANSWER 28 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001-314448 CAPLUS
DOCUMENT NUMBER: 135:119854
TITLE: Catechol derivatives of aminopyrazine and cell protection against uvb-induced mortality

FAMILY ACC. NUM. COURT: 3
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001007401 A1 20010201 WO 2000-JP4726 20000714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV,
LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, TW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2000060160 A5 20010213 AU 2000-60160 20000714
PRIORITY APPLN. INFO.: JP 1999-20298 A 19990723
JP 1999-211702 A 19990727
WO 2000-JP4726 W 20000714

OTHER SOURCE(S): MARPAT 134:131548
GI




AB The title compds. I (A, B and C are each an aromatic carbo- or hetero-cyclo or the like, with the proviso that when A is an optically substituted five-membered heterocycle, W1 is a bond, the same applying in the case of B and W2 and that of C and W3; X and X' are each O, NH, or the like; Y is lower alkyl, lower alkenyl, or the like; V1 and V2 are each a single bond or the like; Ra and Rb are each hydrogen, lower alkyl, lower alkenyl, or the like; further details on Ra and Rb are given; n is 0 to 2) are prepared. Several compds. of this invention at 40 mg/kg/day orally for 10 days suppressed the production of IgE in a mouse model. Formulations are given.

IT 321982-04-1P

EL: BAC (Biological activity or effector, except adverse); BIU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of tricyclic compds. as allergy inhibitors, immunosuppressants, and IgE production inhibitors)

RN 321982-04-1 CAPLUS

CN 2-Propenoic, O-[5-(2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino]-1,1'-biphenyl-4-yl)pyrazinyl]oxime (9CI) (CA INDEX NAME)



AUTHOR(S): Cavalier, J.-F.; Burton, M.; Dussart, F.; Marchand, C.; Rees, J.-F.; Marchand-Brynaert, J.

CORPORATE SOURCE: Unite de Chimie Organique et Medicinale, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.

SOURCE: Biorganic & Medicinal Chemistry (2001), 9(4), 1037-1044

CODEN: BMCECP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 5-aryl- and 3,5-bis-aryl-2-amino-1,4-pyrazine derivs. and related imidazolopyrazinones has been synthesized. The aryl groups of which are catechol and/or phenol substituents. These compds., tested against human keratinocyte cells stressed by UVB irradiation, showed high antioxidant properties. One compound was more active than EGCG/EGC (green tea extract) in reducing cell mortality.


IT 350819-15-7P

EL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(catechol derivs. of aminopyrazine and cell protection against UVB)

RN 350819-15-7 CAPLUS

CN 1,3-Benzenediol, 4-(5-aminopyrazinyl)- (9CI) (CA INDEX NAME)




IT 154616-04-3P

EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (catechol derivs. of aminopyrazine and cell protection against UVB)

RN 154616-04-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 29 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001-78356 CAPLUS

DOCUMENT NUMBER: 134:131548

TITLE: Preparation of tricyclic compounds as allergy inhibitors, immunosuppressants, and IgE production inhibitors

INVENTOR(S): Tanimoto, Norihiko; Inagaki, Masanao

PATENT ASSIGNEE(S): Shimogai & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001-78351 CAPLUS

DOCUMENT NUMBER: 133:79433

TITLE: Apparatus and process for preparing crystalline particles

INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2000038811 A1 20000706 WO 1999-GB43630 19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CR, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6482438 B1 20021119 US 1999-348948 19990707

CA 2356987 A 20000704 CA 1999-2356897 19991222

BR 9916587 A 20010925 BR 1999-16587 19991222

EP 1144065 A1 20011017 EP 1999-962413 19991222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI

TR 200101845 T2 20011222 TR 2001-200101845 19991222

JP 2002533205 T2 20021008 JP 2000-590755 19991222

IT 3588050 B2 20041110 19991222

NZ 512400 A 20030228 NZ 1999-512400 19991222

AU 759880 B2 20030501 AU 2000-18771 19991222

NO 2001003039 A 20010822 NO 2001-3039 20010619

ZA 2001005070 A 20020920 ZA 2001-5070 20010620

PRIORITY APPLN. INFO.: GB 1998-28721 A 19981224

WO 1999-GB4368 W 19991222


AB A process for preparing crystalline particles, especially particles of a pharmaceutical or carrier substance suitable for inhalation therapy is described, in addition to an apparatus for the preparation of such particles. An example is given for the distribution of particles of crystalline fluticasone propionate.

IT 212778-82-0 CAPLUS

EL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (apparatus and process for preparing crystalline particles)

RN 212778-82-0 CAPLUS

CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 31 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:335409 CAPLUS
 DOCUMENT NUMBER: 132:334474
 TITLE: Preparation of spiroindolines as Y5 receptor antagonists
 INVENTOR(S): Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihui; Morin, Nancy R.; Fukami, Takeshi; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd., et al.
 SOURCE: PCT Int. Appl., 130 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027845	A1	20000518	WO 1999-US26447	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LS, LT, LU, LV, MA, MD, MO, MX, MN, MW, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				
RU: GH, GM, KE, LS, MW, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2350714	AA	20000518	CA 1999-2350714	19991108
US 6191160	B1	20010220	US 1999-436120	19991108
EP 1129089	A1	20010905	EP 1999-971808	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 756797	B2	20030123	AU 2000-14732	19991108
US 6313298	B1	20011106	US 2000-656698	20000907
US 2002058813	A1	20020516	US 2001-896940	20010629
US 6495559	B2	20021217		
US 6638942	B1	20030128	US 2002-228250	20020826
US 2004063942	A1	20040401	US 2003-624414	20030721
PRIORITY APPLN. INFO.:			US 1998-10785P	P 19981110
			US 1999-436120	A3 19991108
			WO 1999-US26447	W 19991108
			US 2000-558698	A3 20000907
			US 2001-896940	A3 20010629
			US 2002-228250	A3 20020826

OTHER SOURCE(S): MARPAT 132:334474
 GI



AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl, R4, R5 = H, nitro, etc.] are prepared. I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-[5-(2-pyrazinyl)spiro(indoline-3,4'-piperidine)-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.


IT 268536-93-26 268536-94-3P

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of spiroindolines as Y5 receptor antagonists)

RN 268536-93-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-[5-(2-methoxyphenyl)pyrazinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

AB 268536-94-3 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(2-chlorophenyl)pyrazinyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 32 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:161266 CAPLUS
 DOCUMENT NUMBER: 132:194395
 TITLE: Preparation of pyrazines as anticonvulsants
 INVENTOR(S): Cox, Brian; Bealy, Mark Patrick; Wild, Deborah
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 40 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012498	A1	20000309	WO 1999-EP6248	19990826
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LS, LT, LU, LV, MD, MO, MX, MN, MW, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				

SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM

RU: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341543 AA 20000309 CA 1999-2341543 19990826

AU 9956249 A1 20000321 AU 1999-56249 19990826

BR 9913183 A 20010515 BR 1999-13183 19990826

EP 1107960 A1 20010620 EP 1999-942919 19990826

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

TR 20010603 T2 20010723 TR 2001-20010603 19990826

JP 20020523499 T2 20020730 JP 2000-567518 19990826

TW 429255 B 20010411 TW 1999-88114723 19990827

US 6503909 B1 20030107 US 2001-762295 20010208

US 2003022904 A1 20030130 US 2002-216399 20020812


PRIORITY APPLN. INFO.: GB 1998-108801 A 19980828

WO 1999-EP6248 W 19990826

US 2001-762295 A1 20010208

OTHER SOURCE(S): MARPAT 132:194395

GI



AB The title compds. I [R1 = Ph substituted by one or more halogen atoms; R2 = NH2, R3 = NH2, H; R4 = CONHArB, CNH(CH2)yNHArB (wherein X = O, S; y = 0-2; Ra, Rb = H, alkyl; NHArB = (un)substituted saturated 5-6 membered heterocycle containing one or two N atoms)], useful in the treatment of CNS diseases such as epilepsy, were prepared and formulated. E.g., a multi-step synthesis of pyrazine I [R1 = 2, 3, 5-C13CH2; R2 = R3 = NH2; R4 = CONH2] was given. Compds. I showed ED50 of 1.4 mg/kg compared to 6.1 mg/kg for lamotrigine with a therapeutic index (ratio of the ataxia ED50 and MES ED50) of 21.6 compared to 3.3 for lamotrigine.


IT 259828-60-9P

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of pyrazines as anticonvulsants)


RN 259828-60-9 CAPLUS

CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)


BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of tricyclic compds. as immunosuppressants and allergy inhibitors)
 RN 234428-40-1 CAPLUS
 CN Pyrazinamine, 5-(2,5-dimethyl-4'-(3-methyl-2-butenyl)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234428-41-2 CAPLUS
 CN Pyrazinamine, 5-(3'-fluoro-2,5-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234428-42-3 CAPLUS
 CN Pyrazinamine, N-cyclohexyl-5-(2,5-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234428-43-4 CAPLUS
 CN Pyrazinamine, N-cyclohexyl-5-(3'-fluoro-2,5-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234428-44-5 CAPLUS




RN 234428-49-0 CAPLUS
 CN Pyrazinamine, 5-(3'-fluoro-2,3,5,6-tetramethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)



RN 234428-50-3 CAPLUS
 CN Pyrazinamine, 5-(3'-fluoro-2,3,5,6-tetramethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234428-51-4 CAPLUS
 CN Pyrazinamine, 5-(4'-amino-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl)-N-(3-methyl-2-butene)yl]-(9CI) (CA INDEX NAME)




RN 234428-52-5 CAPLUS
 CN Pyrazinamine, N-(3-methyl-2-butene)-5-[2,3,5,6-tetramethyl-4'-(3-methyl-2-butene)amino][1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)


CN Pyrazinamine, 5-(2,5-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butene)-(9CI) (CA INDEX NAME)




RN 234428-45-6 CAPLUS
 CN Pyrazinamine, 5-(3'-fluoro-2,5-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butene)-(9CI) (CA INDEX NAME)




RN 234428-46-7 CAPLUS
 CN Pyrazinamine, 5-(2,5-dimethyl-4'-(3-methyl-2-butene)amino)[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butene)-(9CI) (CA INDEX NAME)




RN 234428-47-8 CAPLUS
 CN Pyrazinamine, 5-(4'-(bis(3-methylbutyl)amino)-2,5-dimethyl[1,1'-biphenyl]-4-yl)-N-(3-methyl-2-butene)-(9CI) (CA INDEX NAME)




RN 234428-48-9 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butene)-4'-(5-(3-methyl-2-butene)oxy)pyrazinyl]-(9CI) (CA INDEX NAME)




RN 234428-53-6 CAPLUS
 CN Pyrazinamine, 5-(3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butene)-(9CI) (CA INDEX NAME)



RN 234428-60-5 CAPLUS
 CN 2(1H)-Pyrazinone, 5-(3'-fluoro-2,3,5,6-tetramethyl-4'-(3-methyl-2-butene)oxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 234429-20-0 CAPLUS
 CN Pyrazinamine, 5-(2,5-dimethoxy-3,6-dimethyl-4-[6-(3-methyl-2-butene)oxy]-3-pyridinyl)phenyl]-(9CI) (CA INDEX NAME)




RN 234429-21-1 CAPLUS
 CN Pyrazinamine, 5-(2,5-dimethoxy-3,6-dimethyl-4-[6-(3-methyl-2-butene)oxy]-3-pyridinyl)phenyl]-(9CI) (CA INDEX NAME)


RN 212779-07-2 CAPLUS
 CN Propanamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 212779-09-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 212779-13-0 CAPLUS
 CN Pyrazinecarboxonitrile, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-17-4 CAPLUS
 CN 2,6-Pyrazinediamine, 3-methyl-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)


RN 212779-39-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)





RN 212779-41-4 CAPLUS
 CN 2,6-Pyrazinediamine, 3-bromo-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-42-5 CAPLUS
 CN Pyrazinecarboxaldehyde, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-43-6 CAPLUS
 CN Benzenesulfonic acid, 4-methyl-, [(3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl)methylene]hydrazide (9CI) (CA INDEX NAME)




IT 212779-29-66 212779-35-66 212779-38-99
 212779-39-06 212779-41-46 212779-42-59
 212779-43-69
 RL: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazines as anticonvulsants)
 RN 212779-29-6 CAPLUS
 CN Acetamide, N-[6-amino-5-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-35-6 CAPLUS
 CN Acetamide, N-[6-amino-5-(2,5-dichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 212779-38-9 CAPLUS
 CN Propanamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 35 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:482779 CAPLUS
 DOCUMENT NUMBER: 129:227130
 TITLE: Bioluminescent properties of fluorinated semi-synthetic aequorins
 AUTHOR(S): Hirano, Takashi; Ohmiya, Yoshihiro; Maki, Shojiro; Niwa, Haruki; Hashi, Mamoru
 CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Tokyo, 182, Japan
 SOURCE: Tetrahedron Letters (1998), 39(31), 5541-5544
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Bioluminescent properties of semi-synthetic aequorins containing coelenterazine analogs I (X = H, F) possessing fluoro group(s) on the 6-(4-hydroxyphenyl) group match the fluorescent behavior of the phenolate anions of the corresponding fluorinated coelenteramide analogs II. This indicates that the phenolate anion of coelenteramide is the light-emitter in aequorin bioluminescence.


IT 212842-96-18
 RL: BPT (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation and bioluminescent properties of fluorinated semi-synthetic aequorins)

RN 212842-96-1 CAPLUS
 CN Benzeneacetamide, N-[5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-4-hydroxy- (9CI) (CA INDEX NAME)




IT 212842-99-4P 212843-01-1P
 EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and bioluminescent properties of fluorinated semi-synthetic aequorins)

RN 212842-99-4 CAPLUS
 CF Pyrazinamine, 5-[2,3-difluoro-4-(phenylmethoxy)phenyl]-3-(phenylmethyl)-(9CI) (CA INDEX NAME)



RN 212843-01-1 CAPLUS
 CN Phenol, 4-[5-amino-6-(phenylmethyl)pyrazinyl]-2,3-difluoro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:613880 CAPLUS
 DOCUMENT NUMBER: 127:293247
 TITLE: Preparation of pyrrolopyrazines as GABA_A receptor ligands
 INVENTOR(S): Blum, Charles; Hutchinson, Alan
 PATENT ASSIGNEE(S): Neurogen Corp., USA
 SOURCE: U.S., 16 pp., Cont.-in-part of U.S. 5,606,059.
 CODEN: USXKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5668283	A	19970316	US 1995-486595	19950607
US 5210200	A	19940215	US 1992-476409	19921112
US 5606059	A	19970225	US 1995-436254	19950512
US 5910590	A	19990608	US 1997-531648	19970907
US 1992-075409 A2 19921112				
US 1995-436252 A2 19950512				
WO 1992-US10870 W 19931110				
US 1995-486595 A1 19950607				


PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 127:293247
 GI



AB Title compds. (I; R = (un)substituted Ph, -thiethyl, -pyridyl, R4R5 = (CH₂)_nCH12ZCH2 or CH₂Z12CH2; R1, R2, R6 = H or alkyl; Z = NR3, CO, CH(OH), alkoxycarbonylmethine, etc.; R3 = H, (phenyl)alkyl, Ph, alkoxy, etc.; Z1 = NCR15; R15 = H, halo, (phenyl)alkyl, etc.; Z2 = CH or H; n = 0-2) were prepared. Thus, 2,5-F(Me)C6HCOCHO was cyclocondensed with H2NCH2CONH2 and the product converted in 4 steps to I (R = C6H43(CMe)F-5,2, R4R5 = (CH₂)4). Data for biol. activity of I were given.


IT 154032-60-7P
 EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolopyrazines as GABA_A receptor ligands)

RN 154032-60-7 CAPLUS
 CS 2(1H)-Pyrazinamine, 5-(2-fluoro-5-methoxyphenyl)-, hydrazone (9CI) (CA INDEX NAME)



L5 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:99369 CAPLUS
 DOCUMENT NUMBER: 124:146199
 TITLE: Preparation of 2,3-dicyanobenzofuro[2,3-b]pyrazine derivatives as fluorescent substances
 INVENTOR(S): Matsunaka, Masaru; Matsuhina, Yoshimasa
 PATENT ASSIGNEE(S): Takamago Perfumery Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07247288	A2	19950926	JP 1994-65424	19940310
JP 07247288 A2 19950926 JP 1994-65424 19940310				
PRIORITY APPLN. INFO.: OTHER SOURCE(S): CASREACT 124:146199; MARPAT 124:146199 GI				



AB Fluorescent 2,3-cyanobenzofuro[2,3-b]pyrazine derivs. (I; Y, Z = H, lower alkyl, lower alkoxy, di(lower alkyl)amino) provided that at least one of Y and Z = di(lower alkyl)amino are prepared by cyclocondensation of 2,3-dihalo-5,6-dicyanopyrazine (II; Y = halo) with phenol derivs. (III; R = H, HO-protecting group; A, B = H, lower alkyl, lower alkoxy, di(lower alkyl)amino) under heating in solvent followed by treatment with an alkali or acid. Thus, 398 mg 2,3-dichloro-5,6-dicyanopyrazine was dissolved in 50 mL toluene, followed by adding dropwise a solution of 274 mg 3-dimethylaminophenol in 5 mL toluene, and the resulting mixture was refluxed for 24 h to give, after workup and alumina column chromatog., 306 mg I (Y = H, Z = NMe₂). The latter compound showed the maximum absorbency at 430 nm and the maximum fluorescence at 528 nm, in EtOH.

IT 173339-00-9P
 EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of dicyanobenzofuro[2,3-b]pyrazine derivs. as fluorescent substances)


RN 173339-00-9 CAPLUS
 CN Pyrazinacarbonitrile, 5-chloro-6-(2-(dimethylamino)-6-hydroxyphenyl)-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:541426 CAPLUS
 DOCUMENT NUMBER: 122:290892
 TITLE: Preparation of diphenylpyrazine derivatives as herbicides
 INVENTOR(S): Yanai, Toshiaki; Tsukamoto, Yoshihisa; Sakamoto, Takanori; Teramura, Masahiro; Yamada, Toyokuni
 PATENT ASSIGNEE(S): Sankei Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07033752	A2	19950203	JP 1993-176525	19930716


PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 122:290892
 GI



AB The title compds. (I; R1 = H, alkyl, alkoxycarbonylmethyl; R2 = alkyl optionally halogenated by 1-3 halogen atoms, alkoxy, alkenyl, OH, cyclohexyl, PhO, pyridylcyclohexoxy, (un)substituted NH₂; R3 = H, alkyl, NO₂, NH₂, cyano, halo, PhCO, CH₂Ph, alkoxycarbonyl, alkoxycarbonylmethoxy, R4, R5 = H, halo, alkyl, alkoxy; A = O, S(O)_n (wherein n = 0,1,2), NH₂, NH, NH₃; m = 0,1), which show excellent herbicidal activity for weeds of rice paddy such Echinochloa crus-galli, broad leaf weeds, and Scirpus juncoides, are prepared. The herbicidal composition contains I and the active ingredients. Thus, 2,3-dicyanobenzofuro[2,3-b]pyrazine was slowly added dropwise to a suspension of NaH in DMF under ice-cooling followed by adding Et₃Br-methacetoate drycipe and the resulting mixture was stirred at room temperature for 1.5 h to give 100% Et₃Br (5,6-diphenyl-2-pyrazinyl)acetate (II). II at 50 g/are inhibited the growth of E. crus-galli, broad leaf weed, Eleocharis acicularis, Cyperus serotinus, Eleocharis kuroguwai, and S. juncoides by 91-100% in potted paddy soil, whereas rice seedlings were not damaged.

IT 162928-08-7P
 EL: AGI (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diphenylpyrazine derivs. as herbicides)

RN 162928-08-7 CAPLUS
 CN Acetic acid, [(5,6-bis(2-chlorophenyl)pyrazinyl)oxyl- ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1994:508837 CAPLUS
 DOCUMENT NUMBER: 121:108837
 TITLE: Liquid crystalline di-, tri- and tetrafluorophenylpyrazines
 INVENTOR(S): Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William
 PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany

SOURCE: Brit. UK Pat. Appl., 22 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2272216	A1	19940511	GB 1992-23244	19921104
PRIORITY APPLN. INFO.:			GB 1992-23244	19921104
OTHER SOURCE(S):			MARPAT 121:108837	GI



I



II

AB Phenylpyrazine derivs. (I; R1, R2 = (un)substituted alkyl or alkenyl; L1, L2 = H, F) useful as components of liquid-crystalline phases in liquid crystal display devices (no data), are prep'd. Thus, (difluorophenyl)pyrazine II was prepared from PrCOMe in 4 steps.


IT 156573-06-7P

EL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as liquid crystal)

RN 156573-06-7 CAPLUS

CN Pyrazine, 2-(2,3-difluoro-4-propoxyphenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)



LS ANSWER 40 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:269377 CAPLUS

DOCUMENT NUMBER: 121:83377

TITLE: (Biphenyl)pyrazines for liquid crystalline media
INVENTOR(S): Brown, John; Williams, Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Brit. UK Pat. Appl., 40 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English


JP 3314367 B2 20020812 JP 1992-13167 19920128

PRIORITY APPLN. INFO.: MARPAT 120:269942

GI



I



II


AB The title compds. (I; R1 = H, Cl-4 alkyl, alkoxy; R2 = H, Cl-10 alkyl, N-mucinimidyl, n = 1-10) are prepared. I react with biol. important substances such as antigens, antibodies, hormones, drugs, drug metabolites, toxins, and alkaloids to form luminescent compds. and thus are used as reagents for luminescent anal. and chemiluminescence immunoassay (no data). Thus, iso-Pr levulinate was oxidized by SeO2 in iso-PrOH at 80° to give 50% glyoxal derivative HOOCCH2CH2CO2CHMe2 which was cyclized with 2-amino-6-(p-methoxyphenyl)pyrazine in the presence of concentrated HCl in iso-PrOH at 70° to give a phenylimidazopyrazine derivative (II; R2 = iso-Pr). The latter compound was hydrolyzed in 3N HCl at 60° to give 60% II (R2 = H). Addnl. 9 I were prepared

IT 154616-04-3

EL: ECT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with glyoxal derivative)

RN 154616-04-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:245160 CAPLUS

DOCUMENT NUMBER: 120:245160


TITLE: Preparation of indolopyrazines and related compounds as brain GABA_A agonists, antagonists, or inverse agonists

INVENTOR(S): Blum, Charles; Hutchison, Alan


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2271351	A1	19940413	GB 1992-21139	19921008
PRIORITY APPLN. INFO.:			GB 1992-21139	19921008
OTHER SOURCE(S):			MARPAT 121:83377	GI



I



II

AB Biphenylpyrazines I (R1, R2 = , haloalkyl, etc.; x = 0-2) were disclosed. Also claimed were [(cyclohexyl)phenyl]pyrazines. Liquid crystal media and electrooptical devices containing I are claimed. An example compound,

2-Pentyloxy-5-(4-(4-propyl-1,1'-biphenyl)-4-yl)pyrazine (II) was prepared

IT 156467-05-7P

EL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as liquid crystal)

RN 156467-05-7 CAPLUS

CN Pyrazine, 2-(4-butoxyl-2,3-difluorophenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)

LS ANSWER 41 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:269942 CAPLUS

DOCUMENT NUMBER: 120:269942

TITLE: Preparation of Cypridinida's luciferin derivatives as luminescent probes for chemiluminescence immunoassay

INVENTOR(S): Sawada, Hideo; Totani, Yoshiaki; Mitani, Motchiro; Ichikawa, Hideji; Matsumoto, Takeo

PATENT ASSIGNEE(S): Nippon Oils & Fats Co Ltd, Japan

SOURCE: JPKYAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 052866976	A2	19931102	JP 1992-13167	19920128

AB: $R^1, R^3 = H$


$\sqrt{K} = C$




I



II



III



IV

LS ANSWER 40 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:269942 CAPLUS

DOCUMENT NUMBER: 120:269942

TITLE: Preparation of Cypridinida's luciferin derivatives as luminescent probes for chemiluminescence immunoassay

INVENTOR(S): Sawada, Hideo; Totani, Yoshiaki; Mitani, Motchiro; Ichikawa, Hideji; Matsumoto, Takeo

PATENT ASSIGNEE(S): Nippon Oils & Fats Co Ltd, Japan

SOURCE: JPKYAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 052866976	A2	19931102	JP 1992-13167	19920128

AB: $R^1, R^3 = H$


$\sqrt{K} = C$




I



II



III



IV

LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:245160 CAPLUS

DOCUMENT NUMBER: 120:245160

TITLE: Preparation of indolopyrazines and related compounds as brain GABA_A agonists, antagonists, or inverse agonists

INVENTOR(S): Blum, Charles; Hutchison, Alan

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5286690	A	19940215	US 1992-975409	19921112
WO 9411374	A1	19940526	WO 1993-US10870	19931110

AB: AT, AU, BR, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LZ, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, US, VN, ZA

EW: AT, DE, DK, ES, FR, GR, IE, IT, LU, MC, NL, PT, SE, FR, BJ, CP, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9455526 A1 19940608 AU 1994-55526 19931110

US 5606059 A 19970225 US 1995-436252 19950512

US 5668283 A 19970916 US 1995-486595 19950607

PRIORITY APPLN. INFO.: US 1992-975409 A 19921112

WO 1993-US10870 W 19931110

US 1995-436252 19950512

OTHER SOURCE(S): MARPAT 120:245160

GI For diagrams, see printed CA issue.

AB: Title compds. (I; ring Q: O1, O2 = 0-2; R1 = H, alkyl; Y = various organic and inorg. substituents; A = aromatic group substituted with various organic and inorg. substituents; A = CH, N; B = (substituted) C, N; and E = B alkyl). These compds. are highly selective agonists/antagonists or inverse agonists for GABA_A brain receptors. These products claimed are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overactive with benzodiazepine type drugs, and enhancement of alertness. Thus, glycaminide was cyclized with 2-fluoro-5-methoxyphenyl glycol to give 5-(2-fluoro-5-methoxyphenyl)pyrazin-2-one. This was chlorinated with POCl₃ followed by condensation with hydrazine to give 2-hydrazino-5-(2-fluoro-5-methoxyphenyl)pyrazine. The latter was condensed with cyclohexanone to give the hydrazone, which was refluxed in diethylenglycol to give title compound I. I showed IC₅₀ = 0.200 μM for binding to GABA_A receptors.

IT 154032-58-3P 154032-60-7P 154032-61-8P

EL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, as intermediate for GABA_A receptor ligand)

RN 154032-58-3 CAPLUS

CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)- (9CI) (CA INDEX NAME)

AB: $R^1, R^3 = H$


$\sqrt{K} = C$



I



II



III



IV

LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:245160 CAPLUS

DOCUMENT NUMBER: 120:245160

TITLE: Preparation of indolopyrazines and related compounds as brain GABA_A agonists, antagonists, or inverse agonists

INVENTOR(S): Blum, Charles; Hutchison, Alan

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5286690	A	19940215	US 1992-975409	19921112
WO 9411374	A1	19940526	WO 1993-US10870	19931110

AB: AT, AU, BR, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LZ, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, US, VN, ZA

EW: AT, DE, DK, ES, FR, GR, IE, IT, LU, MC, NL, PT, SE, FR, BJ, CP, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9455526 A1 19940608 AU 1994-55526 19931110

US 5606059 A 19970225 US 1995-436252 19950512

US 5668283 A 19970916 US 1995-486595 19950607

PRIORITY APPLN. INFO.: US 1992-975409 A 19921112

WO 1993-US10870 W 19931110

US 1995-436252 19950512

OTHER SOURCE(S): MARPAT 120:245160

GI For diagrams, see printed CA issue.

AB: Title compds. (I; ring Q: O1, O2 = 0-2; R1 = H, alkyl; Y = various organic and inorg. substituents; A = aromatic group substituted with various organic and inorg. substituents; A = CH, N; B = (substituted) C, N; and E = B alkyl). These compds. are highly selective agonists/antagonists or inverse agonists for GABA_A brain receptors. These products claimed are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overactive with benzodiazepine type drugs, and enhancement of alertness. Thus, glycaminide was cyclized with 2-fluoro-5-methoxyphenyl glycol to give 5-(2-fluoro-5-methoxyphenyl)pyrazin-2-one. This was chlorinated with POCl₃ followed by condensation with hydrazine to give 2-hydrazino-5-(2-fluoro-5-methoxyphenyl)pyrazine. The latter was condensed with cyclohexanone to give the hydrazone, which was refluxed in diethylenglycol to give title compound I. I showed IC₅₀ = 0.200 μM for binding to GABA_A receptors.

IT 154032-58-3P 154032-60-7P 154032-61-8P

EL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for GABA_A receptor ligand)

RN 154032-58-3 CAPLUS

CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)- (9CI) (CA INDEX NAME)

AB: $R^1, R^3 = H$

$\sqrt{K} = C$

I

II

III

IV


LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:245160 CAPLUS


DOCUMENT NUMBER: 120:245160

TITLE: Preparation of indolopyrazines and related compounds as brain GABA_A agonists, antagonists, or inverse agonists


INVENTOR(S): Blum, Charles; Hutchison, Alan



RN 154032-61-8 CAPLUS
CN 2(1H)-Pyrazinamine, 5-(2-fluoro-5-methoxyphenyl)-, cyclohexylidenhydrazone (9CI) (CA INDEX NAME)



LS ANSWER 43 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992-571380 CAPLUS
DOCUMENT NUMBER: 117:171380
TITLE: Metalation of diazines. VI. Metalation of pivaloylaminopyrazine and N-tert-butylpyrazinamide. Unusual regioselectivity in the metalation reaction.
AUTHOR(S): Turck, A.; Ple, N.; Trodai, D.; Ndzi, B.; Queguiner, G.
CORPORATE SOURCE: Lab. Chim. Org. Fine Heterocyclique, INSIA, Mt. St. Aignan, 76131, Fr.
SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal Article
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:171380
AB Metalation of (pivalamido)pyrazine and N-(t-butyl)pyrazinamide were studied. For (pivalamido)pyrazine the yields were poor and some addition products were isolated. The metalation of t-butylpyrazinamide was successful and a curious regioselectivity was highlighted.
IT 143769-10-2P, 3-Benzyl-2-(pivalamido)-5-methylpyrazine
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective preparation of)
RN 143769-10-2 CAPLUS
CN Propanamide, 2,2-dimethyl-3-(phenylmethyl)-5-(2,4,6-trimethylphenyl)pyrazinyl - (9CI) (CA INDEX NAME)




LS ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1982-35307 CAPLUS
DOCUMENT NUMBER: 96:35307
TITLE: 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 881,300, abandoned.
CODEN: USXKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4393552	A	19811006	US 1979-62393	19790731
PRIORITY APPLN. INFO.:		US 1978-881300 A2 19780227		
GI				



AB 2-amino-5-(4-bromophenyl)-6-methylpyrazine and the mixture was stirred overnight to give I (R = Cl, R1 = Me, R2 = 4-BrC6H4).
IT 59489-79-1 59816-56-4 80346-73-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(addition reaction of, with chlorobenzoyl isocyanate)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 59816-56-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 80346-73-8 CAPLUS


CN Pyrazinamine, 5-(2-chlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)



IT 69816-72-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)
RN 69816-72-4 CAPLUS
CN Benzamide, 2-chloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl - (9CI) (CA INDEX NAME)




IT 69816-87-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69816-87-1 CAPLUS
CN Benzamide, 2-chloro-N-[(6-methyl-5-(2-methylphenyl)pyrazinyl)amino]carbonyl - (9CI) (CA INDEX NAME)




LS ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1980-1620777 CAPLUS
DOCUMENT NUMBER: 93:220777
TITLE: Substituted 2-aminopyrazines
INVENTOR(S): Barnes, Charles J.; Bannick, Thomas L.; Hoying, Richard C.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 11 pp.
CODEN: USXKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4211870	A	19800709	US 1979-27630	19790406
DK 8001442	A	19801007	DK 1980-1442	19800402
FI 8001056	A	19801007	FI 1980-1056	19800402
AU 8057102	A1	19801009	AU 1980-57102	19800402
PR 2453159	A1	19801031	PR 1980-7457	19800402
BR 8002079	A	19801125	BR 1980-2079	19800402
ES 490287	A1	19810516	ES 1980-490287	19800402
CS 215055	P	19820730	CS 1980-2293	19800402
CA 1157860	A1	19831129	CA 1980-34961	19800402
BE 882608	A1	19801003	BE 1980-9771	19800403
EP 18144	A1	19801029	EP 1980-301085	19800403
R: DE, GB, NL, SE				
GB 2046751	A	19801119	GB 1980-11363	19800403
GB 2046751	A1	19801119		
DD 150057	C	19810812	DD 1980-220207	19800403
ZA 8002005	A	19811125	ZA 1980-2005	19800403
HU 26151	O	19830928	HU 1980-817	19800403
SU 932989	A3	19820530	SU 1980-2902455	19800404
RO 79384	P	19820625	RO 1980-100722	19800404
JP 55141473	A2	19801105	JP 1980-45114	19800405
PRIORITY APPLN. INFO.:		US 1979-27630 A 19790406		
GI				




AB 2-Amino-5-phenylpyrazines I [n = 0, 1, 2 (R = H, halo, alkyl, CF3); R1 = H, alkyl; R2 = alkyl] were prepared from the resp. α -halobenzyl ketoximes II (Y = Cl, Br) and H2NCH2CN (R1 same as above); H2NCH2CN were treated with II and base to yield hydroxymino-substituted aminocetomides III, and the III were cyclized by polyphosphoric acid, H3PO4, or H3PO4-P2O5 at 50-140° to give I. Thus, H2NCH2CN was N-alkylated by 4-BrC6H4CH2C(=O)(OH)Me and Et3N, and the III (Rn = 4-Br, R2 = Me, R1 = H) product was heated with polyphosphoric acid to give I (Rn = 4-Br, R2 = Me, R1 = H).
IT 75411-09-5F 75411-10-8F 75411-11-9F
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 75411-09-5 CAPLUS
CN Pyrazinamine, 5-(2-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 75411-10-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 75411-11-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)-6-methylpyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



LS ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1979:540598 CAPLUS
DOCUMENT NUMBER: 91:140598
TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 19 pp.
CODEN: USXKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4160834	A	19790710	US 1977-861733	19771219
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 3608000	B	19810126		
PRIORITY APPLN. INFO.:				
		US 1974-507492	A2 19740519	
		US 1975-595904	A2 19750714	
		US 1977-775813	A2 19770309	
		AT 1975-7146	A 19750917	

61




I


AB Adding benzoyl isocyanates to aminopyrazines gave ureas I (R, R1 (same or different) = halo, Me, CF3; R2, R3 (same or different) = H, alkanoyl, alkoxycarbonyl; R4 = H, halo, alkyl, cycloalkyl, haloalkyl, NO2, cyano, naphthyl, (C6H5)2C6H42m (n = 0, 1; Z = halo, haloalkyl, alkyl, alkoxy, alkylthio, alkylsulfonyl, NO2, cyano, Ph; m = 0, 1, 2, 3.), KtCH42m (X = O, S, SO2; Z and as above); R5 = H, halo, Me, Et, cyano, haloalkyl), which were insecticidal. Thus, stirring 2-amino-5-chloropyrazine in cold Et2O with 2,6-C12C6H4C(=O)NCO overnight gave I (R = H1 = R4 = Cl, R2 = R3 = R5 = H).
IT 59489-79-1 69816-56-4 71553-78-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(addition reaction of, with benzoyl isocyanate derivative)


RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 71553-78-1 CAPLUS
CN Pyrazinamine, 5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




IT 59489-64-4F 71544-77-9F 71544-80-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverb); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl


11 - (9CI) (CA INDEX NAME)



RN 71544-77-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(6-methyl-5-(2-methylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



RN 71544-80-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2-chlorophenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



LS ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1979:152238 CAPLUS
DOCUMENT NUMBER: 90:152238
TITLE: 1-(Mono-*o*-substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Noemi Henry
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Ger. Offen., 86 pp.
CODEN: GWXKBY
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2826893	A1	19790118	DE 1978-2026893	19780619
US 4133956	A	19790109	US 1977-819639	19770727
IL 54928	A1	19820228	IL 1978-54928	19780615

IL 64263	A1	19820930	IL 1978-64263	19780615
FR 2398738	A1	19790223	FR 1978-18187	19780616
FR 2398738	B1	19810508		
IN 149912	A	19820520	IN 1978-C6466	19780616
BE 868228	A1	19791219	BE 1978-8936	19780619
GB 2001053	A	19790124	GB 1978-27260	19780619
GB 2001053	B2	19820526		
AU 516505	B2	19810604	AU 1978-37249	19780619
AU 7837249	A1	19800103		
GB 2066806	A	19810715	GB 1980-19107	19780619
GB 2066806	B2	19820818		
AT 7804456	A	19811015	AT 1978-4456	19780619
AT 367046	B	19820525		
CA 1129861	A1	19820817	CA 1978-305703	19780619
HU 3227	O	19830830	HU 1978-E1793	19780620
HU 180726	B	19830429		
RO 78069	P	19830803	RO 1978-94410	19780620
HU 29287	O	19840130	HU 1982-1470	19780620
HU 185336	B	19850128		
DK 7802793	A	19781223	DK 1978-2793	19780621
SE 7807127	A	19781223	SE 1978-7127	19780621
NL 7806678	A	19781228	NL 1978-6678	19780621
BR 7803939	A	19790220	BR 1978-3939	19780621
ZA 1980353	A	19800247	ZA 1978-4553	19780621
CS 198014	F	19800520	CS 1978-4555	19780621
CS 1980105	P	19800520	CS 1978-0519	19780621
CS 198106	F	19800530	CS 1978-0520	19780621
SU 789662	D	19810123	SU 1978-2628947	19780621
CH 638500	A	19830930	CH 1978-6770	19780621
JP 54009288	A2	19790124	JP 1978-76343	19780622
ES 471057	A1	19800116	ES 1978-471057	19780622
DD 141831	C	19800521	DD 1978-206203	19780622
DD 143721	C	19800910	DD 1978-213690	19780622
PL 115711	B1	19810430	PL 1978-207831	19780622
ES 471879	A1	19790201	ES 1978-471879	19780719
CA 1103251	A1	19810616	CA 1978-308083	19780725
FR 2398739	A1	19790223	FR 1978-32550	19781117
FR 2398739	B1	19821105		
IL 64216	A1	19821231	IL 1979-64216	19780615
AT 8101716	A	19820415	AT 1981-1716	19810415
DK 8103054	A	19810709	DK 1981-3054	19810709
SE 8303206	A	19830607	SE 1983-3206	19830607

PRIORITY APPLN. INFO.:

IL 1977-819639 A 19770622

IL 1978-819639 A 19770727

IL 1978-54928 A 19780615

AT 1978-4456 A 19780619

GB 1978-27260 A 19780619

DK 1978-2793 A 19780621

SE 1983-3206 A 19830607

GE 1977-26093 A 19770622

US 1977-819639 A 19770727

IL 1978-54928 A 19780615

AT 1978-4456 A 19780619


GB 1978-27260 A 19780619

DK 1978-2793 A 19780621

2-C16C64CONCO to give I (R = Cl, R1 = H, R2 = 4-BrC6H4, R3 = Me, X = Y1 = N), which at 5 ppm gave 100% kill of Spodoptera eridania larvae.


IT 59816-72-49
EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); (preparation and insecticidal activity of)

RN 69816-72-4 CAPLUS
CN Benzamide, 2-chloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




IT 69816-87-19
RL: SPN (Synthetic preparation); PREP (Preparation); (preparation of)


RN 69816-87-1 CAPLUS
CN Benzamide, 2-chloro-N-[(5-(2-methylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



IT 59489-79-1 69816-56-4
RL: RCT (Reactant); RACT (Reactant or reagent); (reaction of, with benzoyl isocyanate)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
CN Pyrazinamine, 5-(2-methylphenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:509584 CAPLUS
DOCUMENT NUMBER: 69:109584
TITLE: Insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John Louis
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 15 pp.
CODEN: USXKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4083977	A	19780411	US 1976-742940	19761118
US 3984137	A	19761005	US 1975-595504	19750714
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		

PRIORITY APPLN. INFO.: US 1974-507492 A2 19740919
US 1975-595504 A3 19750714
AT 1975-7146 A 19750917

GI




I


AB The title compds. I (R = R1 = H, R2 = unsubstituted, halo, Cl-6 alkyl, C3-6 cycloalkyl NO2, CN, Cl-4 alkyl-substituted benzyl, R2, R3 = H, Cl-4 alkanyl, Cl-3 alkoxycarbonyl; R4, R5 = halo, Me, F3C) were prepared. Thus, 2-amino-5-chloropyrazine (II) was treated with 2,6-C16C64CONCO to give 3-(5-chloro-2-pyrazinyl)-1-(2,6-dichlorobenzoyl)urea (III). II was prepared by chlorination of the 2-amino-3-pyrazinecarboxylate followed by hydrolysis and decarboxylation. At 50 ppm III completely controlled southern armyworm after 4 days.

IT 59489-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); (preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




IT 59489-79-1
RL: RCT (Reactant); RACT (Reactant or reagent); (reaction of, with dichlorobenzoyl isocyanate)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:509324 CAPLUS
DOCUMENT NUMBER: 69:509324
TITLE: 1-Benzyl-3-pyrazinylureas
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JXKAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 5201205	A2	19770126	JP 1976-1426	19760101
PRIORITY APPLN. INFO.:			US 1975-595904	A 19750714


GI



AB I (R = H, Cl, Me, (substituted)Ph, etc.; R1 = H, Cl, Me, Et, CN, or R2 = benzo, R2 = Cl, Me) were prepared by reaction of 2-amino-5-R-6-R1-pyrazoles (II) with benzoyl isocyanates 2,6-C16C64CONCO III. I are agricultural insecticides. Thus, 0.25 g II (R = Ph, R1 = H) and 0.45 g III (R2 = Cl) in AcOEt were stirred overnight to give the corresponding I.


IT 59489-79-1
RL: RCT (Reactant); RACT (Reactant or reagent); (cyclization of, with benzoyl isocyanate, benzoylpypyrazinylurea derivative

from) RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT 59489-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); (preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




LS ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:421468 CAPLUS
DOCUMENT NUMBER: 69:21468
TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Ger. Offen., 70 pp.
CODEN: GWYBYX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2541116	A1	19760408	DE 1975-2541116	19750915
DE 2541116	C2	19850719		
IN 142286	A	19770616	IN 1975-CA1744	19750910
BE 770099	A1	19760411	BE 1975-100077	19750911
480092	A1	19770311	IL 1975-8692	19750912
AU 7591445	A1	19770324	AU 1975-94945	19750915
GB 1521714	A	19780816	GB 1975-37933	19750916
CA 1070308	A1	19800122	CA 1975-235561	19750916
NL 7510901	A	19760322	NL 1975-10901	19750917
ZA 7505945	A	19770427	ZA 1975-5945	19750917
SE 7517146	A	19771015	AT 1975-7146	19750917
CS 195710	P	19800239	CS 1975-6398	19750917
DK 7504195	A	19760320	DE 1975-4195	19750918
SE 7510474	A	19760322	SE 1975-10474	19750918
SE 426066	B	19821206		
SE 426066	C	19830317		

PL 102954 P 19790531 PL 1975-197527 19750918
 PL 106054 P 19791130 PL 1975-183470 19750918
 CH 617192 A 19800514 CH 1975-12147 19750918
 HU 19446 O 19810228 HU 1975-EI646 19750918
 HU 177200 P 19810228
 JP 51056480 A2 19760518 JP 1975-114226 19750919
 BR 7506073 A 19760803 BR 1975-6073 19750919
 FR 2299327 A1 19760827 FR 1975-28772 19750919
 FR 2299327 B1 19780407
 DD 123341 C 19761212 DD 1975-108451 19750919
 ES 441124 A1 19770616 ES 1975-441124 19750919
 DD 128762 C 19771207 DD 1975-196898 19750919
 SU 662011 D 19790505 SU 1975-2171811 19750919
 SU 660566 D 19790430 SU 1976-2380308 19760709
 AT 7705635 A 19800615 AT 1977-5635 19770729
 AT 360800 B 19810126
 SE 7806517 A 19780602 SE 1978-6517 19780602
 SE 420042 B 19810914
 SE 420042 C 19820107
 PRIORITY APPLN. INFO.: US 1974-507492 A 19740919
 AT 1975-7146 A 19750917


GI



AB Insecticidal dichlorobenzoylaminopyrazines I [R = Cl, Ph, H, Me, Br, Et, substituted phenyl, CH₂Me₂, CH₂Me₃, R1 = H, Me, Cl, CN; R2I = substituted (CH₂)₄] (29 compds.) were prepared by treating aminopyrazines II with 2,6-Cl₂CH₂CONCO, obtained by treating 2,6-Cl₂CH₂CONH₂ with (COC₂)₂. At 1000 ppm I gave complete control of *Spodoptera eridania*.
 IT 59489-64-47
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPA (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and insecticidal activity of)
 RN 59489-64-4 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



IT 59489-79-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with dichlorobenzoyl isocyanate)
 RN 59489-79-1 CAPLUS
 CN Pyrasinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1973:537092 CAPLUS
 DOCUMENT NUMBER: 79:137092
 TITLE: Pteridines. XXIX. Uniquely vocal route to 2,4-diamino-6-substituted pteridines
 AUTHOR(S): Taylor, Edward C.; Perlman, Katherine L.; Kim, Young-Ho; Sword, Ian P.; Jacobi, Peter A.
 CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, USA
 SOURCE: Journal of the American Chemical Society (1973), 95(19), 6413-18
 CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB 2,4-Diamino-6-substituted pteridines (I) are prepared. Reaction of an α -keto-aldoxime with aminomalononitrile gives 2-amino-3-cyano-5-substituted pyrazine 1-oxides which yield 2,4-diamino-6-substituted pteridines upon cyclization with guanidine. 2,4-Diaminopteridines are then obtained by decyanation of the corresponding 6-oxides, or alternately by prior decyanation of these pyrazine 1-oxides, followed by cyclization with guanidine. The conversion of 2-amino-3-cyano-5-methylpyrazine 1-oxide to the corresponding 1,4-dioxide, and a number of chemical transformations of this latter intermediate, are also described.

IT 50627-21-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclization of, diaminopteridine from)

RN 50627-21-9 CAPLUS

CN Pyrasinecarbonitrile, 3-amino-6-(2-methoxyphenyl)-, 6-oxide (9CI) (CA INDEX NAME)



** LOGOFF
 ALL LN QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
 LOGOFF? (Y/N/HOLD): Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL
 240.23 402.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY TOTAL
 -27.01 -27.01

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:52:32 ON 29 JUN 2005